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ABSTRACT 
Determining the conformational dynamics of enzymes as they undergo catalysis has been 
challenging for decades due to the short timescale and limitations of traditional analysis, 
including techniques such as CPMG 2D NMR and X-ray crystallography. Herein is the study of two 
proteins: TEM-1 β-lactamase, the most common enzyme responsible for the hydrolysis of 
antibiotics in gram-negative bacteria, and yeast alcohol dehydrogenase (YADH), responsible for 
facilitating the hydride transfer to NAD+ for energy production in prokaryotes. In the catalysis of 
both antibiotics and NAD+ reduction the specific residues involved in each binding mode remain 
under debate. By using a microfluidics workflow and an adjustable reaction volume, time 
resolved HDX experimentation was used to monitor deuteration events concurrently with 
catalytic activity on the millisecond to second timescale. Native mass spectrometry enabled 
studies into binding affinity and monitoring of substrate inactivation on a measured time course. 
Ion mobility mass spectrometry (IM-MS) was used to provide definitive MS/MS results for protein 
coverage and prov ide spatial resolution for all protein/substrate complexes. Additionally, 
collision induced unfolding (CIU) within the ion mobility cell provides a comparative binding 
affinity scale for the inhibitory drugs used in the study of TEM-1. Using this wide range of 
analytical techniques facilitated important discoveries including the isolation of specific residues 
of TEM-1 mapped to their involvement in different binding modes during catalysis, and 
subsequently the differentiation in inactivation pathways depending on substrate concentration 
and type. Further work has isolated residues involved in the turnover event of NAD+ along with 
residues that display a significant decrease in dynamics with the catalysis of deuterated ethanol 
compared to the non-deuterated ethanol.  
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1. Introduction 
1.1 Mass Spectrometry 
Mass spectrometry is the science of measuring atomic mass, first reported in the early 20th 
century by J.J. Thomson. Thomson was the first to report on isotopes and the electron, thus 
advancing our knowledge of atomic masses and generating a new field of science. Thomson’s 
work was greatly influenced by the earlier work of Wilhelm Wien1, who decades earlier 
discovered that particles within a cathode ray would deflect under the influence of an electric 
field with a velocity proportional to the mass of the particle.  Wien proposed that the angle and 
velocity of deflection within the cathode ray is only reproducible by particles of identical mass, 
thus generating a new field of science with high mass specificity.  
The field of mass spectrometry has ballooned in the last century with great advancements made 
in ionization methods and mass detectors, that lower the limit of detection and increase the mass 
sensitivity of the instruments, making mass spectrometry a vital component of analytical 
chemistry2. Mass spectrometers can now be used at atmospheric pressure and with soft 
ionization methods that do not destroy the sample using two methods: matrix assisted laser 
desorption ionization (MALDI)3 and electrospray ionization (ESI)4. Both techniques are 
considered relatively gentle, as the species under study is not degraded during the ionization 
process and entrance into the instrument.  
 
1.1.1 Electrospray Ionization (ESI) 
Due to the gentler nature of ionization, electrospray ionization is often used in biological sciences 
as a method that can analyze proteins at physiological conditions. ESI-MS is extremely useful in 
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the field of catalysis, as it allows for immediate on-line analysis of a reaction as it is occurring. 
This could prove to be crucial for the determination of enzyme-catalyzed products5. Due to the 
formation of multiply-charged ions during ESI, this technique is especially useful in the detection 
of high mass analytes on instruments with limited m/z range6,7. ESI was a technique popularized 
by John Fenn8 as a means of  creating a link between liquid chromatography and traditional 
gaseous mass spectrometry analysis. In brief, a sample is vaporized at the ion source by being 
passed through a heated capillary with an electric potential applied, often with the addition of a 
volatile solvent to aid in protonation or deprotonation of the species9,10. A potential difference 
of a few kV is supplied between the capillary needle and the chamber walls of the mass 
spectrometer (the counter electrode)7. The potential applied at the capillary can be either 
positive or negative. In positive ion mode, the positive charge applied to the capillary causes the 
negatively charged ions participating in the electrochemical reaction to flow towards the capillary 
walls, generating a solution with primarily positively charged ions along the capillary axis and the 
negatively charged analytes are along the capillary walls. With this concentration of charged ions 
along the capillary axis, there is an accompanying decrease in pH and formation of positively 
charged analyte ions from a neutral analyte due to the interaction with solvent (usually H3O+) as 
the solution nears the tip of the capillary: 
        𝑀 +𝐻+ → [𝑀 + 𝑧𝐻]𝑧+                                                (1) 
Where M is the analyte and z is the number of charges/protonation events occur during the 
formation of the analyte ions. The composition of the charged liquid will be altered to contain 
mostly positively-charged ions (in the case of a positive voltage applied to the capillary) primarily 
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due to the redox reactions occurring at the metal-liquid capillary interface where negative 
potential has built up11,12.  
There are a couple of methods to prevent the charge imbalance buildup that occurs with 
positively charged ions exiting from the capillary tip during electrospray13. If the spray capillary is 
metal, the metal could be ionized and causing a release of electrons to the electrode (equation 
2). Another potential redox reaction would be the removal of negatively charged ions present in 
solution with an oxidation reaction at the metal surface (shown below for aqueous solutions, 
equations 3 and 4)7,14: 
                                                                𝑀(𝑠) → 𝑀
2+
(𝑎𝑞) + 2𝑒
−                                                   (2) 
4𝑂𝐻−(𝑎𝑞) → 𝑂2(𝑔) + 2𝐻2𝑂 + 4𝑒
−                                          (3) 
                                                          2𝐻2𝑂 → 𝑂2(𝑔) + 4𝐻
+ + 4 𝑒−                                             (4) 
The reaction displayed in equation 2 is dependent on the material of the metal electrode, with 
the dominant reaction between equations 3 and 4 dependent on the lowest oxidation 
potential12,13. With a voltage applied to the capillary generating an electric field, an 
inhomogeneous distribution of charged species will occur. Ions  inside the spraying capillary are 
subjected to the electric field (Ec) calculated by Loeb15: 
𝐸𝑐 =
2𝑉𝑐
𝑟𝑐 ln(
4𝑑
𝑟𝑐⁄ )
                                                                  (5) 
Where Vc is the applied potential, rc is the outer radius of the capillary and d is the capillary tip-
counter electrode distance11. The energy required for onset of instability in the Taylor cone (Eon) 
that causes electrospray can be related to equation 5 is given below16: 
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                                                               𝐸𝑜𝑛 = (
2𝛾𝑐𝑜𝑠𝜃0
𝜀0𝑟𝑐
)
1/2
                                                             (6) 
Where 𝛾 is the surface tension of the liquid, 𝜃0 is the half-angle of the liquid cone at the capillary 
tip and 𝑟𝑐 is the inner radius of the capillary. To determine the voltage required for electrospray 
to occur, equations 5 and 6 can be combined. For example, if we substitute  𝜃0=49.3
0 and 𝜀0= 
8.8x10-12 J-1c2m-1, we get the following simplified equation to determine the capillary voltage for 
the onset of electrospray: 
                                                       𝑉𝑜𝑛 =  2𝑥10
5(𝛾𝑟𝑐)
1/2ln (
4𝑑
𝑟𝑐
)                                                (7) 
Ionization of the liquid sample for generating gas phase ions can be split up into three steps: 
nebulization of the liquid sample at the capillary tip, vaporization of neutral solvent molecules 
and ion evaporation of the remaining solvent from the charged droplet7,9,10,17. This positively 
charged solution has repulsive interaction within the capillary, and the strong electric field 
propels the liquid phase ion towards the liquid gas interface, generating a spray of randomly 
charged droplets at the capillary and forming a Taylor cone at the tip (nebulization)9,10,18.  
Charged droplets are ejected and begin to evaporate at the Rayleigh limit (where surface tension 
is equal to coulombic repulsion) and emit as a spray4. Vaporization of the neutral solvent 
molecules and volatile solute (such as ammonium acetate) through desolvation by a 
counterflowing gas causes the radius of the charged droplets to decrease, generating a higher 
field strength at the surface of the charged droplets9,17. These highly charged parent droplets 
travel towards the mass spectrometer, where with increasing repulsion due to increased surface 
charge density and decrease in droplet radius they break apart by fission into progeny droplets 
of various charges4,7,11. The ion stream then enters the ion source at atmospheric pressure, with 
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a gradual reduction in pressure as the ion stream travels through various quadrupoles towards 
the mass analyzer19.  
 
Figure 1.1 Magnification of Electrospray Ionization Droplet Formation in Positive Ion Mode. The 
analyte solution flows through a metal capillary with an electric potential applied. Positive ions 
are repulsed away from the capillary, generating a Taylor cone of positively charged species at 
the tip. When the columbic repulsion exceeds the surface tension of droplets formed, progeny 
droplets are ejected from the large droplets, generating a cycle of fission events. Having a volatile 
solvent along with fission events allows for efficient evaporation of solvent around the charge 
analyte molecules, as the spray droplet size is reduced from µm to nm before entering the mass 
spectrometer (grey box, right) that is the counter electrode of this electrochemical reaction. 
Image depicts at Waters Q-ToF mass spectrometer with a Z-spray ion source. The analyte enters 
into the mass spectrometer orifice where the ion beam is collimated (yellow outline) with 
decreasing pressure as the neutral gas molecules are pumped out of the mass spectrometer by 
the curtain gas.  
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1.1.2 Nanoelectrospray Ionization (nanoESI) 
Nanospray ionization has benefitted protein mass spectrometry considerably. As shown in 
equation 7, the radius of the capillary used in electrospray is linearly proportional to the voltage 
required for spraying to occur. With a smaller radius, the voltage required for ionization is also 
decreased, providing gentler desolvation conditions that can allow for less volatile solvent 
systems17. In addition, a reduction in flow rate within the capillary originally reported an increase 
in desolvation efficiency as 510 times higher with a nanoESI source equipped, likely due to a lower 
potential for clustering and a reduction in curtain gas20. By using a nanoelectrospray source we 
expand the possibilities for physiological conditions at the source and an analysis of non-covalent 
complexes21.  
 
1.1.3 Mechanism of Electrospray Ionization  
In contrast with the electrochemistry occurring at the capillary during electrospray ionization, the 
ionization of the gas phase ions is in free space and can be generated through various 
mechanisms. The ambient gas pressure during ionization is necessary for supressing electric gas 
discharge and maintaining the temperature of the droplets are they undergo continuous 
evaporation12. The manner in which the soft ionization of proteins and other analytes occurs has 
been subject to considerable study, with three prevailing theories as to how the desolvated 
analyte is produced: the charged residue mechanism (CRM), proposed by Dole22;  the ion 
evaporation model (IEM), proposed by Iribarne and Thomson23; and the third theory of the chain 
ejection model (CEM), proposed by Konnermann24. In the CRM, a charged droplet containing one 
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ion within a liquid droplet is expelled through coulombic fission or goes through complete 
evaporation of the liquid exterior in a cycle until the ion remains with little to no solvent12,25. The 
relationship between the charge of the ion and the size of the droplet must not exceed Rayleigh’s 
limiting charge and can be calculated using the following equation: 
                                              𝑒𝑧𝑅 = 𝑞𝑅(𝑅𝑖) = 8𝜋(𝛾𝜀0𝑅𝑖
3)
1
2                                                (7) 
Where 𝑞𝑅 is Rayleigh’s limiting charge for a droplet, 𝛾 is the surface tension of the solvent, and 
𝑅𝑖 is the radius of the large ion. Progeny droplets undergoing evaporation and coulombic ejection 
from parent droplets will have charges lower than 𝑞𝑅 (70-100%)
6,25. 
In contrast to the coulombic repulsion and ejection model of CRM, IEM predicts that low 
molecular weight species will be ejected from the droplet due to the high electric field caused by 
excess charge carriers in the droplet and coulomb repulsion between cationic side chains and 
therefore acquire charge locally, likely with a smaller charge than would be produced by CRM6,24. 
Droplets shrink by evaporation until the field strength is large enough for ions to be ejected from 
the droplet. The energy associated with the large electric field is sufficient to compensate for the 
energy required for the solvated ion expulsion26.  
More simply, the difference between these two theories can be isolated to the method in which 
the analyte molecules separate from each other and the droplet: for IEM, a single analyte is 
present per solvent droplet and will desorb into the gas phase and reduce the coulombic 
repulsion of the droplet. In CRM, this analyte ejection occurs through multiple fission events until 
only one molecule of analyte is present in a droplet11.  
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The CEM theory can be described as a combination of the original two proposals, in that the 
behaviour of the macromolecular analyte is dependent on it’s conformation; species that are 
unfolded or hydrophobic will exhibit IEM-like ejection, while polymers that are folded or 
hydrophilic will behave like the CRM model6.  As protein is unfolded, the polarity of the 
macromolecule changes from hydrophilic to exposing the primarily hydrophobic core, causing 
the polymer chain to migrate towards the droplet surface for ejection due to the electrostatic 
repulsion24,27. The main difference between the CEM and IEM is the way ejection from the solvent 
molecule occurs. For the IEM, the species will acquire charge locally as it is ejecting. In the CEM, 
the species will be ejected in a sequential manner, one charged residue at a time. This generates 
a higher charge on the species than by IEM alone26.  
Bearing these models in mind, native globular proteins are believed to follow the CRM, as 
charged polar residues would be facing the solvent and more susceptible to fission events24, 
while smaller analytes follow the IEM, driven by hydrophobic interactions. The CEM is proposed 
to represent behaviour of proteins under non-native conditions, such as protein unfolding during 
electrospray. 
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Figure 1.2 Electrospray Ionization Evaporation Models. The blue circle represents the charged 
ion, while the larger green circle represents the charged solvent. A) Ion Evaporation Model 
(IEM)23, suggests that low molecular weight species within a droplet will eject and acquire charge 
locally as they exit the charged droplet. B) The Charged Residue Model (CRM)22 proposes that 
the droplet will gradually lose all solvent due to evaporation and the a charged species will retain 
the overall charge of the droplet prior to evaporation (but not exceeding Rayleigh’s limiting 
charge). Given the same species in solution, the IEM process would produce an ionized species 
of lower overall charge. C) The Chain Ejection Model, which depicts the ejection of an unfolded 
protein, that acquires charge locally as ejection is occurring.  
 
1.1.4 Quadrupole Time-of-Flight (Q-ToF) Mass Spectrometers 
Mass spectrometers with a time-of-flight analyzer are now routinely used for the analysis of large 
macromolecular structures, with increasing use in transmission of high m/z species28–30. 
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Quadrupole Time-of-flight instruments (Q-ToFs) are able to combine  high sensitivity and mass 
accuracy for precursor and product ions with a small limit on the size of the species, allowing low 
charge states of macromolecules can be examined19. Traditionally, there are 3 quadrupoles (Q0, 
Q1 and Q2) where ion separation and transmission occur, followed by the time-of-flight (ToF) 
mass analyzer at the back end of the instrument.  
A quadrupole mass filter contains 4 parallel and electrically isolated electrodes that generate a 
hyperbolic electric field between them using both RF and DC-fields, causing ions to be focused 
down the quadrupole center. Q0 operates as the ion guide, responsible for focusing the ion 
beam; Q1 is the mass filter, Q2 is the collision cell (utilizing neutral gas molecules) and the ToF 
carries out the mass separation. In a triple quadrupole instrument, Q0 and Q2 are in RF-only 
mode; this helps confine the ion beam of the parent and fragment ions31. This confinement also 
reduces ion motion, slowing down the flow of ions and reducing beam amplitude into the mass 
analyzer, effectively increasing the quantity of ions reaching the analyzer31. When the 
quadrupoles are used as a mass analyzer, they can operate with both RF and DC-voltages applied, 
with the Mathieu parameters of each component (𝑞𝑀 is for the RF-voltage, 𝑎𝑀 is for the DC-
voltage) calculated using the following equations31: 
                                                       𝑞𝑀 = 
4𝑒𝑉
(
𝑚
𝑧
)𝜔2𝑟0
2  ;   𝑎𝑀 = 
8𝑒𝑈
(
𝑚
𝑧
)𝜔2𝑟0
2                                              (8) 
For the RF-voltage parameter (𝑞𝑀), e is the charge of an electron, ω is the angular frequency and 
V is the amplitude. For the DC-voltage parameter (𝑎𝑀), 𝑈 is the DC-voltage, and 𝑟0 is the radius 
of the quadrupole. When in RF-only mode, the quadrupoles rely only on the 𝑞𝑀 parameter, with 
ions that have a 𝑞𝑀<0.908 being rejected during the mass filtering
31.  
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For tandem MS, the Q1 operates as a mass filter, allowing only the parent ion of interest to pass 
into Q2. Within Q2, the ions undergo collision induced dissociation (CID) after collisions with 
neutral gas molecules (generally argon or nitrogen). After collisions, the ions are again focused 
by the RF-field and re-accelerated into a parallel beam for entrance into the ToF analyzer31. At 
the entrance of the ToF, an orthogonal electric field is pulsed through the ion beam, pushing the 
ions into the accelerating column, where mass separation occurs28. Because the ions are 
accelerated with the same energy, ions with different m/z will acquire different velocities and 
reach the mass detector at different rates.  
In order to avoid spectral overlap of the pulsed ion beams passing through the ToF analyzer, an 
injection pulse at the modulator cannot be applied until after the slowest ion has reached the 
detector at the end of the analyzer. The slowest ions will travel a distance D and have an ion 
beam length ∆l that can be detected, generating an upper limit to the duty cycle of this particular 
m/z value that can be calculated using the following:  
                                                        𝑑𝑢𝑡𝑦 𝑐𝑦𝑐𝑙𝑒 (
𝑚
𝑧
) =  
∆𝑙
𝐷
√
𝑚/𝑧
𝑚/𝑧𝑚𝑎𝑥
                                                                   (9) 
Where m/zmax is generated from the flight time that is the inverse of ToF pulse frequency31. Most 
ToF instruments operate with a duty cycle of 5-30%8. The resolution of in a ToF mass 
spectrometer is calculated as: 
                                                     𝑅𝐹𝑊𝐻𝑀 = 
𝑚
∆𝑚
= 
𝑡
2∆𝑡
= 
𝐿𝑒𝑓𝑓
2∆𝑧
                                                            (10) 
Where ∆m and ∆t are the peak widths measured at half mass and time (respectively), m and t 
are the mass and flight times of the ion, ∆z is the thickness of the ion packet and Leff is the effective 
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length of the ToF analyzer. The relationship between the flight time of the ion and the mass of 
the ion is: 
                                                                𝑡 =  
𝐿𝑒𝑓𝑓
√2𝑒𝑈𝑎𝑐𝑐
 √𝑚/𝑧                                                           (11) 
Where Uacc  is the accelerating voltage in the ToF31. Although the mass range that a ToF can 
analyze is unlimited in theory, there are practical limitations that arise based on the availability 
of the ion transmission through the quadrupoles, dependent on the RF amplitude28. The highest 
m/z value achievable at the quadrupole of each instrument (Mmax) can be calculated using the 
following equation: 
𝑀𝑚𝑎𝑥 =
7∗106𝑉𝑚 cos(2𝜋𝑓𝑡)
𝑓2𝑟0
2       (12) 
Where Vmcos(2πft) is the applied RF voltage (the oscillation rate of the alternating current) 
applied between rods, f is the frequency (Hz), t is the time of transmission (s) and ro is the inner 
radius of the quadrupoles (m)28. The safest way to increase mass range in a ToF instrument is by 
increasing the frequency, to the detriment of instrument resolution (shown in equations 10 and 
11). For high resolution, a narrow transmission window is required, lowering the amount of duty 
cycles that are carried out by the mass spectrometer.  
Mass spectra for ESI-MS are recorded using a time-to-digital converter (TDC) at the end of the 
ToF channel, with a multiple anode detector as an add on for increasing the dynamic range of 
this ion-counting technique. The TDC records the arrival time of the electric pulse in conjunction 
with the start time of the same pulse, generating a spectrum of arrival times summed over the 
course of the acquisition time.  
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Microchannel plates (MCPs) are another form of detector, that have a flat conversion surface 
area, beneficial for recording large amounts of ion packets (in the y-dimension) in a transient 
manner. They are an analog system that digitizes the ion current.  One significant problem with 
using a MCP as a detector is the time window in which ions hit the detector, as differing degrees 
of penetration will produce a large variation in detection time31. They also do not have a large 
dynamic range, and as such are generally used for MALDI systems.  
 
Figure 1.3 Quadrupole Ion Separation. Ions of various masses (depicted by multiple coloured 
lines) enter through the ion guide (left) in parallel into the quadrupole, which can act as a 
transmission guide (for single MS) or as a mass filter of parent ions (for tandem MS).  The 
quadrupoles are electrodes, with opposing charged rods connected with the same DC voltage 
and RF-field. The applied RF-field generates a potential well that is essential for radially confining 
the ions, providing collisional buffering of ion movement31. Non-resonant ions to the RF-field will 
collapse into the quadrupoles, not passing through to the detector (unlike the resonant ions, in 
blue) of the mass spectrometer.  
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1.2. Ion-Mobility Mass Spectrometry- Introduction 
 
Protein unfolding can be captured using ion-mobility mass spectrometry (IM-MS)32–34, which 
measures the collisional cross-section (CCS) and drift time of ions passing through the IMS cell of 
a mass spectrometer. Travelling-wave IMS is predated by the drift tube IMS (DT-IMS)33, a method 
of separating ions within the collision cell using a high pressure gas environment and a low-
potential electric field to cause ion separation by size. As ions are passing through the weak 
electric field applied to the drift tube, collisions with inert gas molecules will slow down the 
progress of larger ions, generating a separation of ions that is dependent on the ion’s size and 
shape35. This method has the limitation of having high error associated with comparing to 
literature36. In a drift tube, along with the RF-ion confinement there is also a linear voltage 
gradient, responsible for moving the ions along the cell towards the mass analyzer36. Ions move 
through the drift tube with ion velocity proportional to the electric field: 
                                                                               𝑣 = 𝐾𝐸                                                                        (13) 
Where v is the ion velocity, K is the ion mobility and E is the electric field. This ion velocity is used 
to calculate the drift time, related to the length of the drift tube by the following equations: 
                                                                         𝑡𝐷 = 
𝑙𝑒𝑛𝑔𝑡ℎ
𝐾𝐸
+ 𝑡0                                                            (14) 
Where 𝑡𝐷 is the drift time and 𝑡0 is the transport time of ions from the end of the drift region to 
the ToF-mass analyzer. Drift time IMS has very low sensitivity due to the pulsing analysis and 
ensuing reduction in duty cycle due to the time lost between measurement of ion packets32.    
 
Within the drift cell, the length of the cell and potential applied can be varied in order to change 
the average amount of collisions with the drift gas. The time for the ionized species to pass 
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through the mobility cell is correlated to the CCS, with species with a smaller CCS travelling faster 
through the countercurrent drift gas because of reduced drag32. The reduced mobility coefficient 
(K0) can be calculated from the following37: 
 𝐾0 = 
𝐿
𝑡𝐷𝐸
∗  
𝑃
760
∗  
273.15
𝑇
                                                       (15) 
Where L is the length of the drift tube (m), P is the pressure (Torr), tD is the average drift time (s), 
T is the temperature (K) and E is the electric field strength (V/m). Equation 15 does not consider 
the charge state of the species within the mobility cell, which would also influence the drift time 
of the charged ion species. The equation for CCS takes the charge state into consideration. 
            𝛺 =  
(18𝜋)
1
2
16
∗
𝑧𝑒
(𝑘𝐵𝑇)
1
2
∗ [
1
𝑚𝐼
+
1
𝑚𝐵
] ∗
𝑁
𝐾0
                         (16) 
Where z is the charge state, e is the elementary charge (C), T is the temperature (K), kB is the 
Boltzmann constant, mI and mB are the masses of ion and buffer gases (respectively, in kg), and 
N is the neutral gas number density (m-3). With K0 defined in equation 15, and the parameters of 
E, L, P and tD being easily measurable during experimentation, CCS calculations have great 
precision37,38. Using the above calculations, IMS-MS can distinguish species entering the mobility 
cell by size, shape and stability39,40. IM-MS is useful for examining large protein complexes as the 
topography of an ionized complex is sensitive and unique to each sample38,41. Careful 
consideration must be made to optimize the ionization conditions within the mobility cell to 
encourage ion separation but discourage non-covalent complex dissociation, such as reducing 
collisional heating or gas pressure within the collision cell to avoid complex dissociation42–44.   
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1.2.1. Collision Induced Unfolding Mass Spectrometry 
Collision-induced unfolding (CIU) is a relatively new technique used in analytical and medicinal 
chemistry to provide evidence of comparative binding affinity between protein substrates and 
study unfolding pathways45–48. The charged ion species is bombarded with neutral gas at 
increasing voltages within the collision cell of the IMS section of the mass spectrometer to 
encourage intermolecular collisions, eventually leading to complete dissociation of the complex. 
When looking at the same charge state across a panel of protein-ligand complexes, unfolding 
transition states can be visualized using heat maps (see figure 1.4 below), which are used to infer 
comparative binding affinity49. 
 
 
Figure 1.4 A schematic of IM-MS is used to differentiate ligand binding to large protein 
complexes on a Synapt G2. A) Panels of collision voltage (V) vs drift time (ms) of the Concanavlin 
A tetramer with 3 different manosyl sugars: 3α,6α -mannopentaose (M5), 3α,6α-mannotriose-
di-(N-acetyl-D-glucosamine) (M3G2) and 3α,6α mannopentaose-di-(N-acetyl-D-glucosamine) 
(M5G2). Highlight white box is examined on the right. B) Drift times for each complex 
demonstrate the relative stability of each protein-ligand complex. Adapted from Niu et al49. 
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1.2.2. Traveling-Wave Ion Mobility Spectrometry 
On the Waters Synapt G2 instrument, the IMS cell is equipped with travelling-wave (TW-IMS) 
component that significantly increases sensitivity, compared to the traditional drift tube IMS (DT-
IMS) workflow33. The CCS values for TW-IMS are not specifically determined from measured drift 
times as they are in DT-IMS. Instead, they are determined through calibrating ions of interest to 
ions of known CCS values36. This travelling-wave refers to an electric pulse applied to the ion 
guide, causing ion propulsion through the ion guide at a specific radio frequency. This DC 
travelling wave is overlaid over the RF voltage that is already applied to the stack of ion guides, 
causing the ions to be propelled, reducing transit time through the cell32.  
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Figure 1.5 Cross Section of a Travelling-Wave IMS Collision Cell with various CCS50. Ring 
electrodes (in grey) line the collision cell, with a direct current being applied over the typical RF-
voltage. This alternation of current generates a “wave” voltage that moves ions through the cell, 
depicted above as a dotted green line. Depending on the size of the ions, they may remain in the 
collision cell after the voltage pulse passes through (high mobility ions, purple and yellow shapes), 
or be pushed out of the cell, travelling with the wave (low mobility ions, red spheres). More 
compact and aerodynamic ions will travel through the collision cell faster, generating lower 
arrival times than bulkier ions or complexes. Further separation and resolution can be obtained 
by increasing the length of the collision cell.  
 
1.3. Hydrogen Deuterium Exchange 
Hydrogen Deuterium eXchange (HDX) is an analytical probing technique that provides a 
relationship between protein function and dynamics by measuring backbone amide deuterium 
uptake with a variety of experiments51. HDX-MS supplements traditional HDX-NMR labelling by 
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being able to label transient intermediates52 and is incredibly useful for studying the 
conformational dynamics of intrinsically disordered proteins53, antibody/antigen binding54 and 
mapping catalytic processes to binding modes55.HDX-MS is particularly useful due to the low 
quantity of protein required and ability to separate heterogeneous mixtures with 
chromatographic systems51. HDX-MS can also be used to study unfolding rates and kinetics, such 
as myoglobin56. For example, Chait and Katta used the HDX technique as a means of probing 
global conformational dynamics of proteins by mass spectrometry as an alternate to the more 
popular solution-phase NMR or circular dichroism, to identify protein intermediates57,58. By 
incubating bovine ubiquitin in deuterium, followed by acidification with deuterated acetic acid, 
they were able to demonstrate an increase in charge state with unfolding after a range of 
incubation times followed by an analysis of the various protein states elucidated.  Currently, HDX-
MS of proteins is most often carried out through a “bottom-up” proteomics workflow, 
popularized by Smith59, that entail the following steps: incubation of protein in deuterium, 
followed by an acidic quenching step and proteolytic digestion before entering the ion source of 
a mass spectrometer. Through bottom-up HDX analysis, amino acid-level resolution can now give 
global structural information into protein dynamics60. 
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Figure 1.6 Schematic of a bottom-up proteomics HDX workflow. Protein is displayed with labile 
hydrogens in black. After deuteration, some labile hydrogens have been replaced with 
deuterium, depending on the time of incubation and dynamic nature of the protein. Following 
an acidic quenching step to drastically reduce the rate of back exchange, the deuterated protein 
is digested by proteolytic enzymes, such as pepsin or protease XVIII. Following digestion, the 
peptide mass shifts with and without deuteration are recorded. The relative isotopic distributions 
of peptides with deuteration (bottom left, in yellow) compared to without (bottom left, green) 
demonstrate the amount of deuterium uptake (recorded as a mass increase or as a percentage 
of the overall number of exchangeable hydrogens) on average for that peptide.   
 
1.3.1. Fundamental Theory 
Hydrogen/Deuterium exchange was first theorized by Linderstrom-Lang, who examined the 
deuteration rate of insulin and proposed the theory of protein dynamics and hydrogen exchange 
that we use to this day61,62. In solution there is a constant hydrogen exchange with solvent as 
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protein fluctuates between various conformational states, limited only by the pKa of each 
functional group associated with each amino acid. Main chain amides exchange more slowly than 
other hydrogen groups in the primary structure, and their exchange rate can be easily 
manipulated through temperature and pH variation to be measurable on a ms-s timescale63–65. 
HDX can be carried out in acidic or basic environments. The acid-catalyzed exchange being 
facilitated through an amidate mechanism66,67 while the base-catalyzed mechanism operates 
through N-protonation or O-protonation.  
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Figure 1.7 Schematic of acid (B and C) and base (A)-catalyzed hydrogen/deuterium exchange 
reactions mechanisms with backbone amides. A) Base-catalyzed exchange, where OD- 
deprotonates the amide group, generating an amidate ion which is then protonated by D2O. B) 
Acid-catalyzed exchange, where the N-atom of the amide is responsible for deprotonating D3O+, 
followed by deprotonation of the amide to remove the proton.  C) Acid-catalyzed exchange, with 
the amide O-atom initiating protonation with D3O+, followed by acidification of the NH proton 
and formation of an imidic acid. Adapted from Weis68. 
 
Although the N-protonation mechanism is favoured, the O-protonation pathway is more basic. 
With either type of catalyzed exchange reaction, the rate of back exchange with the solvent is 
limited by a decrease in temperature and pH, with 00 C and a pH of 2.5 providing the slowest rate 
of back exchange69–71.  
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Figure 1.8 A chevron plot of logkex vs pH for two peptides, poly-D, L-alanine (PDLA) and poly-D, 
L-lysine (PDLL) protium/tritium exchange reactions. The original experiment that demonstrated 
the effect of pH on amide hydrogen exchange rates, showing a minimum rate of exchange in the 
pH range of 2.0-3.0 for both PDLL and PDLA species. Heavy isotope exchange was measured after 
incubation in tritium and column separation to remove excess tritium at fixed time points. 
Concentration of tritiated polymer was measured spectroscopically. Adapted from Englander and 
Poulsen69. 
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As shown in the original work of Englander and Poulsen, in the pH range of 2.5-3.0, acid and base-
catalyzed exchange mechanisms have approximately the same rate (see figure 1.8) for proteins 
(and peptides)68,69. Below pH 2.0, exchange reactions are primarily acid-catalyzed, while above 
pH 3.0, base-catalyzed exchange is most common. Therefore at physiological conditions (pH 7) 
the base-catalyzed mechanism is favoured68. By reducing the pH of the solution after the 
deuteration event, the rate of exchange will decrease by up to 4 orders of magnitude, making an 
acidic quenching step ideal for efficient and accurate HDX analysis68,69. In general, protein 
dynamics are thought to fluctuate between several conformations, with the most simplistic 
model of deuteration events depicting a rate of “open” and “closed” conformations, referring 
specifically solvent accessibility for deuteration events to occur with main chain amide groups. 
𝑁𝐻𝑐𝑙
𝑘𝑜𝑝
→  
𝑘𝑐𝑙
←  
𝑁𝐻𝑜𝑝
𝑘𝑐ℎ
→ 𝑁𝐷                 (17) 
Where kop is the rate of protein unfolding/opening, kcl is the rate of folding/closing and kch is the 
chemical exchange rate (dependent on experimental conditions)64. Under steady state 
conditions, the rate can be calculated with the following equation63: 
   𝑘𝑒𝑥 = 
𝑘𝑜𝑝𝑘𝑐ℎ
𝑘𝑜𝑝+𝑘𝑐𝑙+𝑘𝑐ℎ
                (18) 
Assuming a stable structure (kcl >> kop), equation 18 reduces to: 
           𝑘𝑒𝑥 = 
𝑘𝑜𝑝𝑘𝑐ℎ
𝑘𝑐𝑙+𝑘𝑐ℎ
               (19) 
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There are two other conditions for protein dynamics to take into consideration. For a bimolecular 
exchange, EX2, it is assumed that the rate of protein refolding is much faster than the exchange 
can occur (kcl >> kch).  
            𝑘𝑒𝑥 = 
𝑘𝑜𝑝𝑘𝑐ℎ
𝑘𝑐𝑙
                           (20) 
Under the above scheme, it is assumed that isotopic exchange with backbone amide would be a 
rare event, likely occurring after multiple cycles of fluctuations between open and closed 
formations72. For a monomolecular reaction, EX1, conditions that promote exchange (kch>> kcl, 
high pH, high temperature) simplify the steady state exchange equation even further: 
                                                                        𝑘𝑒𝑥 = 𝑘𝑜𝑝                                                                         (21) 
Although both conditions are possible, the EX2 scheme is more common amongst stable 
proteins72 while EX1 is more common with denaturation conditions73. 
 
1.3.2. Pulsed vs. Continuous Labelling Conditions for HDX 
The field of proteomics in mass spectrometry has expanded rapidly in the new millennium, with 
the study of proteins ranging from discovery, to function determination, to molecular medicine74. 
HDX experiments are traditionally carried out with a continuous labelling method, first employed 
in the study of protein unfolding kinetics by measuring changes in charge state through acid 
denaturation75. In brief, protein is exposed to deuterium and the rate of deuteration is measured 
over time as an increase in protein mass72.  This increase in mass over time is an averaging of all 
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the protein dynamics in solution at a specific time, and as such does not identify where 
deuteration is occurring in the global structure68.  
Pulse labelling experiments are typically carried out with quenching steps (by acid or a different 
solvent) and have a known observation time to determine transient intermediate species, with 
minimum reaction times of a few seconds being achievable52,76–78. The time points selected for 
quenching are longer than the exchange time, allowing for the deuteration to be monitored at 
various parts of the reaction68. The reaction is carried out inside an observation cell, where data 
acquisition begins once the liquid flow is detected and the protein species is no longer at 
equilibrium76. Limitations of this pulsing workflow initially included the inability to observe 
reaction occurring without absorption or fluorescence spectroscopy, which would reduce the 
number of species that could be studied.  
 
1.3.3. Time-Resolved Hydrogen Deuterium Exchange 
Millisecond-second scale HDX was a fortunate byproduct of using a microfluidics workflow to 
interface ESI-MS with an on-line analytical technique. Work by Kern et al with NMR relaxation 
techniques has demonstrated that the dynamics observed on the ps-ns timescale of amide bond 
fluctuation have direct influence on the µs-ms timescale global fluctuations79. Time-resolved ESI 
enables an accurate examination of protein dynamics in solution or gas phase56,80; the ms-s 
timescale is especially useful for monitoring transient intermediate species in pre-steady state 
conditions81, ligand binding82,83, protein unfolding and catalysis75,84.   As data is acquired using 
this kinetic workflow, it is possible to calculate rate constants, turnover number and the 
dissociation constant for a variety of proteins to uncover reaction mechanisms5,85. Coupled with 
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a proteolytic digestion step, many  groups have reported complete protein digestion with a 
variety of samples within a few seconds of incubation86.  
 
 
Figure 1.9 Schematic of the Wilson Group Time-Resolved HDX Capillary Workflow Top) 
Overview of the microfluidics workflow and PMMA chip used for bottom-up HDX analysis. The 
yellow box highlights the magnification shown below. Bottom) An inner glass capillary containing 
the protein sample has a soldered end with a small notch engraved 2 mm away from the edge. 
For continuous labelling HDX, the microfluidics device must have efficient mixing to ensure non-
laminar flow within the microcapillaries.  With this notch, the protein sample is able to flow out 
of the inner capillary into the larger metal capillary, which contains deuterium and mix efficiently. 
With known flow rates, capillary dimensions and fixed reaction volume before quenching, the 
time of deuteration can be easily calculated. After deuteration, the reaction is quenched at a T-
mixer by an acidic solution (right). For experiments involving substrate/ligand binding, 
traditionally the substrate is introduced concurrently with the deuteration event to map 
conformational dynamics specifically to protein: substrate interactions. 
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1.3.4. Microfluidic Devices for Hydrogen Deuterium Exchange 
A reduction in size of any analytical system involving fluid dynamics will have a dramatic increase 
in sensitivity, transportation time to the detector and better resolution87,88. It is with these 
principles in mind that microfluidics devices have been devised for use with an electrospray 
source on a mass spectrometer. ESI-MS carried out on a microfluidics device requires a nL-µL/min 
flow rate, which is ideal for using a nanoelectrospray source. Microfluidics devices could have an 
ESI interface either constructed into the device or protruding outwards, like a metal capillary89,  
or they may have a nanocapillary interface for efficient chromatography simultaneously through 
electrophoresis90–92. In the past decade, advances have been made to embed proteolytic digest 
within polymeric cells93, reduce the dead volume during analytical separation92,94  and enable a 
nanoLC-chip-MS workflow94.  Additionally within the past year, the Rand group have 
commercialized a microfluidics device for rapid HDX incubation times with quenching and 
deuteration channels built on-line95.   
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Figure 1.10 Schematic of a new generation microfluidics chip.  In this recent advancement to 
the field of microfluidics and sub-second HDX, on-chip deuteration and quenching allows for 
rapid mixing. In addition, thiolene plugs reduce dead volume within the microfluidics channels, 
further reducing the timescale limit for rapid HDX. Adapted from Svejdal et al95. 
 
1.4. Enzymes Producing Antimicrobial Resistance- An Overview 
 
 
1.4.1. Antibiotic Drug Development 
Antibiotics have been used commonly since the discovery of penicillin in the 1929 and have 
ballooned in the pharmaceutical industry96. Antibiotic resistance primarily due to overuse in the 
general population has plagued our advancement in the drug development process due to the 
high mutational rate and adaptability of bacteria along with the emergence of multidrug resistant 
pathogens97–100. Current medical practices typically combine doses of an inhibitory drug in 
conjunction with an older family of penicillins or cephalosporins to provide effective medical 
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treatment101,102. Resistance is now common among the newest Class 3 antibiotics, signaling the 
end of the ability to effectively eliminate bacteria with current medical practices98,103,104.  
 
1.4.2. Role of Penicillin Binding Proteins in Bacterial Cells 
 
The cell wall in prokaryotes is responsible for maintaining the internal osmotic pressure necessary 
for bacterial life and to facilitate cellular growth105–107. Penicillin binding proteins (PBPs) are 
transpeptidases responsible for cross-linking peptidoglycan strands in the bacterial cell wall. The 
glycan chains targeted by PBPs are alternating β-1,4-glycosidic linkages between N-
acetylglucosamine (NAG) and N-acetylmuranic acid (NAM). In the final step of cell wall synthesis, 
the D-ala terminal reside of the NAM sugar is removed108. The acyl-NAM chain then forms amide 
linkage with the terminal L-alanine residue of the peptide L-alanyl-γ-D-glutamyl-L-diaminoacyl-
D-alanine, generating a peptidoglycan strand107,109. PBPs were first implicated in resistance 
mechanisms in the early 1970s106,  and this theory gained traction with the isolation of an evolved 
PBP (PBP-2a) that had low affinity for penicillins110,111.  
31 
 
 
Figure 1.11 Mechanism of Peptidoglycan Formation by Penicillin Binding Proteins in the Cell. A) 
Acylation of the terminal D-alanine residue of the NAM sugar. B) Nucleophilic attack (likely by a 
conserved Lysine residue) generated a protonation event between the glycans. C) The β-1,4-
glycosidic linkage is formed, generating a peptidoglycan strand.  Adapted from Fisher et al108. 
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1.4.3. Generation of β-lactam Antibiotics 
β-lactam antibiotics target the cell wall synthesis of gram-negative bacteria by inhibiting PBPs at 
the Ser403 residue;  the structure of the most common antibiotics contains a β-lactam core that 
mimics the D-Ala-D-Ala terminus of peptidoglycan chains 103,108,112,113, resulting in a cell that goes 
through structural degradation of the cell wall without the PBPs generating new peptidoglycan. 
β-lactam antibiotics are the main form of medication in mass production to treat bacterial 
infections for several reasons: they can be produced in high yield, are stable with several 
variations in functional groups and can be derived at low cost108,114,115. This structural uniformity 
across a medical class has made mutational adaptability to β-lactam drugs straightforward. 
Complete resistance to β-lactam antibiotics and inhibitors has been observed in an increasing 
number of organisms, suggesting that without new approaches, the effectiveness of β-lactam 
drugs may be limited in the long-term116–119. The newest antibiotic, Avibactam120, is a 
diazabicyclooctane inhibitor that has been produced without a β-lactam core. However, its 
effectiveness is still not enough to be ingested alone; it must still be introduced in conjunction 
with an additional β-lactam antibiotic for full treatment. 
 
1.4.3.1. Differences in Antibiotic Families 
Several families of antibiotics have been studied in experiments with TEM-1 to determine their 
efficacy (measured as a kinetic value of the deacylation reaction), but no experiments have yet 
been able to distinguish the specific amino acid residues involved in the digestion of these 
substrates. To overcome β-lactamase mediated antibiotic resistance, a number of β-lactam 
drugs, notably the cephalosporins, have been developed that generate inefficiently hydrolyzed 
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acyl-enzyme intermediates and have increased binding affinity within the active site121–124. Also 
in clinical use are β-lactamase inhibitors that are not antibiotics in themselves (because they do 
not efficiently bind PBPs) but can irreversibly acylate β-lactamases though a series of off-pathway 
intermediates. The current practice with ‘challenging’ pathogens is often to prescribe a β-
lactamase inhibitor in conjunction with older-generation β-lactam antibiotics, but this approach 
is becoming less and less efficient101,125,126. Ampicillin, cephalexin and potassium clavulanate 
were tested as substrates for mapping conformational dynamics with TEM-1. The penicillin family 
of drugs (which includes ampicillin) has been extensively studied kinetically and have 
comparative data to cephalosporins, but there has been no reporting on global changes in TEM-
1 conformational dynamics with these drug substrates. Potassium clavulanate, an irreversible 
covalent inhibitor, was used as a negative control to determine the most inactive/closed 
confirmation possible for TEM-1 as it binds in the active site. 
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Figure 1.12 Chemical structures of β-lactam antibiotics currently on the market. β-lactam drugs 
can be split up into 4 families: penicillins, cephalosporins, monobactams and carbapenems. 
Inhibitors also contain the β-lactam core but possess weaker antimicrobial activity. Adapted from 
Nordmann et al103.  
 
1.4.4. Evolution of β-lactamases 
In an evolutionary response to the appearance of β-lactam drugs in the bacterial cellular 
environment, bacteria have evolved proteins known as β-lactamases, that hydrolyze β-lactams 
before they can inhibit PBPs127–130. Most classes (A, C and D) of β-lactamases contain an active 
site serine that is responsible for the hydrolysis of the lactam ring contained within the β-lactam 
antibiotics120,131,132. This SXXK motif (residues 70-73) is conserved in all Class A β-lactamases and 
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is the primary site of interest in drug development133. Class B β-lactamases are metallo-enzymes 
that coordinate with Zinc ions to effectively hydrolyze the drug substrate125,134,135.  
 
1.4.4.1. TEM-1 β-lactamase Introduction 
Our research is focused on TEM-1, a Class A β-lactamase, the most common form found in E. 
coli136. Hundreds of variants have been discovered and present in resistant forms to all drugs of 
the penicillin family and several of the cephalosporins130,137. Due to it's singular binding site and 
the residues involved in the acylation at the active site there has been rigorous study into the 
residues crucial to impart drug resistance138–141. The reigning consensus is that the omega loop 
(residues 161-179), a structurally conserved SXXK motif (residues 70-73), a general base (Glu166) 
and a series of nucleophiles (Ser70 and Ser130) are the principal regions involved drug binding 
and acylation100,142–147, along with salt bridges to regions outside the active site148.  Early research 
on TEM-1 successfully crystallized the acyl-enzyme intermediate149 and inhibitor-bound150 states 
which are used throughout as a reference for enzymatic activity. Unfortunately, there is still no 
crystallographic structure of the pre-acylation substrate-bound complex, due to the rapid 
kinetics151. The search for allosteric regions in TEM-1 have yielded some results42–44, but has yet 
to lead to new drug design.  
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Figure 1.13 TEM-1 crystal structure with 3 drug families used in TRESI -HDX experiments. A) 
TEM-1 crystal structure (PBD: 1BTL) with secondary structure noted. In bold are H2 and H7, the 
regions associated with binding. On the right is the globular structure with H2 and H7 highlighted 
in blue, with the known allosteric binding region (H11) highlighted in purple. B) Chemical 
structure of the 3 drug substrates studied for binding activity, in order of effectiveness against 
TEM-1 activity (left to right).  
 
1.5. Enzymes Involved in Energy Metabolism 
 
1.5.1. Energy Formation in Prokaryotes and Lower Eukaryotes 
 
The electron transport chain is a vital route for aerobic energy production in many organisms. 
The most common pathway for energy production occurs in the mitochondria with the 
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establishment of a proton gradient to generate ATP via ATP synthase. The proton gradient is 
facilitated primarily through two complexes, labelled as 1 and 2. Both complexes 1 and 2 are 
responsible for the transport of electrons to ubiquinone with proton translocation across 
mitochondrial membrane; complex 1 accepts electrons from NADH, while complex 2 accepts 
electrons from FADH2155. Under anaerobic conditions, the oxidation of NADH occurs via the 
reduction of acetyl-CoA by an alcohol dehydrogenase156. Deficiencies in the electron transport 
chain (such as the reduction of NAD+) can lead to a variety of disorders in humans and other 
organisms157, underscoring the importance of studying binding interactions of these coenzymes 
with their enzymatic partners.  
 
1.5.2. NAD+ and NADH Background 
Nicotinamide adenine dinucleotide (NAD) has multiple functions, most importantly as a 
coenzyme for the hydride transfer in alcohol dehydrogenases. NAD is also a substrate for energy 
consumption in a variety of other enzymatic pathways, including ribosyl transferases and 
glycohydrolases158. NAD was discovered as a potential cofactor for yeast alcohol dehydrogenase 
(YADH) in 1906 by Harden and Young, who were examining the fermentation pathway of yeast 
and postulated that some cofactors were required for yeast to generate carbon dioxide through 
this pathway159. The first examination of the redox potential of NAD was investigated by Otto 
Warburg in 1936 as part of his well-known work elucidating the role of oxidation in cells and 
cancer growth160,161. The oxidative properties of NAD+ in the cytoplasm and mitochondrial matrix 
demonstrated that several prokaryotes and eukaryotes operate with similar NAD+/NADH ratios, 
sustainable for efficient redox reactions162. NAD binding domains within dehydrogenases (such 
38 
 
as yeast) contain a conserved double β-α-β-α-β motif163. It is believed that having a long loop that 
encompasses this expanded sheet creates an ideal cavity for the insertion and binding of the 
adenine ring in NAD+. YADH requires NAD+ as a cofactor for substrate binding to initiate catalysis;  
binding of NAD+ at the C-terminal end forces the enzyme into a more closed configuration to 
force ethanol and NAD+ to react via a zinc ion and a narrowing of the interdomain space164. 
 
 
Figure 1.14 NAD+-facilitated Ethanol Oxidation. The ability of NAD+/NADH to participate in a 
reversible redox reaction makes the cofactor vital to many different enzymatic pathways in lower 
eukaryotes and prokaryotes.  
 
39 
 
1.5.3. Yeast Alcohol Dehydrogenase 
Yeast Alcohol Dehydrogenase (YADH) is the primary enzyme responsible for the reduction  of 
acetaldehyde to ethanol during the glucose fermentation process in prokaryotes and some lower 
eukaryotes165. There are multiple isoforms and isozymes present in a variety of prokaryotes and 
eukaryotes (YADH contains 3 forms166), the principal form being ADH1. Composed of 347 amino 
acid residues, ADH1 YADH has a dynamic quaternary structure and require two cofactors for 
catalysis. Each monomer of YADH contains 2 zinc ions, 1 involved in catalysis (either through a 
tetra- or penta-coordination with a water molecule167) and 1 that maintains structural stability 
away from the active site165. In yeast, the tetrameric form is favoured. Although the tetramer is 
composed of 4 identical subunits, their configuration in quaternary form is different: subunits A 
and C maintain a closed configuration with bound NAD+, while subunits B and D remain open 
with no bound NAD+.  
 
1.5.3.1. Hydride Transfer and Tunneling 
Enzymes accelerate the rate of reaction by stabilizing the transition state complex168. Typically in 
catalysis, reactions follow the transition state theory developed by Pauling169, where a minimum 
activation energy must be obtained before a chemical reaction occurs to produce products with 
a lower, more stable ground state energy170. Tunneling thwarts this assumption, by producing a 
chemical reaction (the hydride transfer) without attaining the minimal energy of the activation 
barrier. This is achievable due to the small mass of hydrogen, a short distance between reacting 
species and a minimal energy barrier171. Given the small size of hydrogen and the short distance 
between the hydride donor and acceptor, quantum mechanical behaviour is predicted on the 
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angstrom scale171–173. Yeast alcohol dehydrogenase provided the first example of hydride 
tunnelling being observed in a macromolecule, first observed by Cha et al174. Hydride transfer is 
occurring between the alpha carbon of the alcohol present (typically ethanol) and the C4 atom 
of the nicotinamide ring in NAD+. The NAD+ molecule may undergo a conformational shift into 
boat conformation to help increase the molecular orbital overlap and decrease the potential 
energy barrier observed in this reaction175. 
 
1.5.4. Kinetic Isotope Effect on Catalysis of Yeast Alcohol Dehydrogenase 
The Kinetic Isotope Effect (KIE) is used to identify the highest energy transition state in catalysis, 
and can help distinguish between concerted and stepwise mechanisms176. To help understand 
the hydride transfer mechanism, several researchers have mapped the KIE of protium and 
deuterium in this catalysis to quantify the remarkable isotopic dependence observed177–179. The 
primary KIE relates to the hydride transfer, while the secondary KIE is due to the aldehyde 
product remaining in the active site. The KIE of YADH was first reported by Cho and Northrop, 
who demonstrated the effect of pressure on catalytic efficiency180. 
 
1.5.5. Mechanism of Catalysis 
The bi-bi mechanism of this redox reaction was originally proposed by Dickinson and Monger181. 
They proposed two steps to the YADH catalytic cycle: binding of the ethanol and the reduction of 
NAD+ to NADH, followed by the release of NADH from the binding site. The reduction step that is 
dependent on the hydride transfer is traditionally considered the “burst” phase of catalysis, while 
the “lag” phase of catalysis is dependent on the turnover and release of NADH from the 
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enzyme171. HDX experiments have attempted to isolate the local dynamics of this burst phase 
with limited results, as the reactions have not been conclusively proven to give observable 
conformational changes on the catalytic timescale171.  
 
 
Figure 1.15 Yeast Alcohol Dehydrogenase Bi-bi Mechanism of the Catalytic Cycle In order for 
the redox reaction to occur, the enzyme must have NAD+ bound as a cofactor prior to ethanol 
binding. Adapted from Liuni et al178. 
 
1.6. Research Objectives 
Medicinal chemistry is constantly adapting to a changing microbial environment that presents 
increasing challenges as new resistance mechanisms develop and drug candidates have limited 
experimentation done on a catalytic time scale to deduce residue-localized binding effects. Using 
time-resolved microfluidic devices, herein we demonstrate the impactful utility of millisecond-
scale HDX on determining conformational dynamics of enzymes as they participate in substrate 
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hydrolysis or redox reactions. Chapters 2-4 all employ millisecond-timescale HDX, with Chapter 
3 also uses the CIU technique and Chapter 4 examines global HDX rates of catalysis to determine 
the effect of deuteration on hydride transfer. 
Chapter 2 examines the contribution of binding modes to catalytic steps in TEM-1 β-lactamase 
and how time-resolved millisecond HDX can be enabled to identify these specific residues during 
the hydrolysis of three different classes of antibiotics. 
Subsequently, in Chapter 3 we further investigate the inhibitory mechanism that is induced 
during the rigidification process of TEM-1 to help understand the potency of each inhibitory drug 
and present a more comprehensive binding affinity scale based on CIU-MS and local HDX results.  
Chapter 4 examines the residue-specific impact of deuterium incorporation into the reduction of 
NAD+ to NADH via YADH and ethanol, and how this allosterically impacts the quaternary structure 
of the YADH complex.   
In conclusion, Chapter 5 discusses the impact of new microfluidic devices for use with more 
complex enzymatic cycles and how this will further influence drug development and structural 
biology. 
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Chapter 2 
Mapping Conformational Dynamics to Individual Steps in the 
TEM-1 β-Lactamase Catalytic Mechanism 
 
 
A version of this chapter was published in the Journal of Molecular Biology: 
 
Knox, R.; Lento, C.; Wilson, D. J. Mapping Conformational Dynamics to Individual Steps in the 
TEM-1 β-Lactamase Catalytic Mechanism. J. Mol. Biol. 2018, 430, 18, 3311-3322.  
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2.1 Summary 
Although the link between conformational dynamics and catalytic activity is commonly discussed, 
very few experiments have been able to conclusively isolate which regions of protein are necessary 
for binding modes. By studying TEM-1, a well-known protein involved in antibiotic resistance, we can 
identify dynamics linked to specific components of catalysis: binding, acylation and deacylation. We 
postulate that using ampicillin (first generation and easily hydrolyzed), cephalexin (second 
generation, with slower deacylation from the binding pocket) and clavulanate (third generation, 
complete inhibition) will demonstrate how each drug class interacts in this enzymatic process. Our 
research aims to discover novel binding sites in TEM-1 that may be targeted for drug development 
and lead to new synthetic pathways for drug synthesis that do not employ traditional lactam bond 
formation, such as isolating residues involved in binding (Glu166, Ser70, Ser130) and identifying 
regions of rigidification necessary for enzymatic inactivation (residues 273-284). 
 
2.2 Introduction 
The most commonly prescribed antibiotics, β-lactams, target cell wall synthesis in bacteria by 
inhibiting Penicillin Binding Proteins (PBPs) from cross-linking peptidoglycan strands in the bacterial 
cell wall112,113. TEM-1 β-lactamase is known to degrade β-lactam drugs near the diffusion limit across 
a wide range of penicillins and cephalosporins182. The rates of acylation and deacylation for different 
drug products and β-lactamase classes have produced indeterminate results. Cephalosporins are 
known to be acylated quickly but have a much slower deacylation rate than ampicillin in class A β-
lactamases along with differing activity137,183,184. This may be in part due to the different interactions 
at the binding site; during acylation, the penicillin carboxylate is bonding to the C3 carbon in the 
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thiazolidine ring (stereogenic) while the cephalosporin carboxylate interacts with the C4 carbon (sp2, 
in a planar orientation)183,185.  Class A β-lactamases in general are known to have a very fast 
deacylation process; the rate limiting portion of the reaction is due to the acylation mechanism186. 
From this information we expected regions with lower deuterium uptake exclusive to the cephalexin 
experiments to be related to the deacylation mechanism. Using our microfluidics device workflow, 
in conjunction with Time Resolved Hydrogen/Deuterium eXchange (TRESI-HDX) (figure 2.1), we can 
monitor the conformational dynamics of each catalytic process within a suitable biological 
environment.  By plotting the differences in deuterium uptake with TEM-1 in holoenzyme and 
apoenzyme form, we can monitor changes associated with drug interactions and not based on native 
conformational fluctuations. Of particular interest are regions that demonstrate changes in dynamics 
with ampicillin and cephalexin but not clavulanate, as this would elucidate which regions of the 
protein are not involved in deacylation, along with potential regions of allostery. Based on 
statistically significant differences in the conformational dynamics of TEM-1 as turnover is occurring, 
we are able to demonstrate how TRESI-HDX can be used to guide drug development for of β-lactams 
and further employ this technique for binding mode analysis in other antimicrobials.  
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Figure 2.1 Schematic depiction of the TRESI-HDX experimental setup. A) The enclosed proteolytic 
chamber (PMMA) digests the deuterated protein sample prior to ESI-MS.  For each 
substrate/inhibitor, the holoenzyme deuterium uptake is compared to the apoenzyme baseline 
uptake recorded on the same day. These experiments differ slightly from conventional HDX in that 
the substrate/inhibitor is introduced to the enzyme concurrently with the onset of HDX labeling on 
the millisecond timescale. This is to ensure that the enzyme is in the steady state, acylated state 
and/or undergoing slow turnover when the uptake measurements are made. B) The crystal structure 
for TEM-1 with secondary structural elements (H1-11 corresponding to helices and S1-5 
corresponding to β-sheets) highlighted (PBD ID: 1BTL). 
 
 
47 
 
2.3 Results and Discussion 
2.3.1 Native MS of TEM-1 and Formation of Acyl-enzyme Intermediates 
Previous reports on TEM-1 inhibition by clavulanic acid used a 1000:1 inhibitor: enzyme ratio 
incubated for 1 hour at room temperature to ensure complete inactivation187. Neither this inhibitor: 
enzyme ratio nor lengthy incubation was possible in our experiment due to ESI compatibility of high 
substrate concentrations and our use of the “kinetic” TRESI workflow for optimal mixing188,189. We 
therefore used native mass spectrometry to characterize the global conformation of the purified 
protein and to determine the minimum concentration of substrate requirements for complete 
inhibition of the protein. These experiments were enhanced by the SpyTag system for optimal 
stability190. Ultimately, these experiments demonstrated that a 10:1 clavulanate: TEM-1 ratio was 
sufficient to generate fully bound protein, observed as a mass shift of 200 Da (fig 2.2). The 
observation of the intact bound inhibitor as a complete molecule is at odds with our current 
understanding of the clavulanate inhibitory mechanism, which is thought to inactivate via off-
pathway processes resulting in the covalent attachment of clavulanate or fragments thereof over 
multiple catalytic cycles138,183,191–194. One possible explanation is that the inhibition process for 
clavulanate is sensitive to reaction conditions, and that under MS-appropriate conditions (200 mM 
NH4Ac, pH 6.7), initial hydrolysis of the intact molecule, corresponding to an expected mass shift of 
198 Da, is highly unfavored195. 
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Figure 2.2 Native Mass Spectra of TEM-1 Binding Clavulanate. Native mass spectrum of TEM-1 
(orange) with clavulanate-incubation after 1 hour (blue) at a ratio of 10:1 inhibitor: enzyme. Inset 
(top right) is the observed mass increase of +200Da at the +19-charge state, approximately 
corresponding to the mass of an intact clavulanate molecule (198 Da).  
 
2.3.2 TEM-1 Conformational Dynamics in the Presence of Substrate, Partial Inhibitor and Covalent 
Inhibitor 
 
We used TRESI-HDX to exclusively monitor the dynamics influenced by the protein: substrate 
interactions of TEM-1 in the presence of ampicillin, cephalexin and clavulanate. TRESI-HDX is a 
valuable tool in studying amide backbone exchange and hydrogen bonding in a protein complex, 
which is especially important when studying the conformational landscape of an enzyme as they 
interact with substrates or inhibitors58,196. By using a kinetic TRESI workflow, we are able to monitor 
conformational dynamics of enzyme catalysis on a millisecond-to-second timescale188,189 and 
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observe the substrates in steady state rapid turnover (ampicillin), slow turnover (cephalexin) or 
covalent inhibition (clavulanate) as the hydrogen/deuterium exchange is occurring.   Figure 2.3 
depicts the relative conformational changes between the substrates and apo-enzyme at 1.54s, with 
each colored bar depicting residues that show significant changes in dynamics. Although the amount 
of residue coverage for each substrate is not identical (ampicillin, 85%; cephalexin, 66%; clavulanate, 
80%), the binding region and known areas of high mutational activity are covered with an 80% overall 
shared coverage. For figure 2.3, regions in red are those with statistically significant increase in 
dynamics relative to the apo-enzyme, while blue regions denote a significant decrease, shown as a 
dotted line (>2σ, n=9). Figure 2.3 gives a broad snapshot of the conformational dynamics 
sequentially, with inference made about the spatial dynamics through large regions of uptake or 
decrease. Appendix A displays results for each kinetic and equilibrated local HDX experiment.  
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Figure 2.3 Time-Resolved Deuterium Uptake for TEM-1 with 3 Substrates. Single time-point TRESI-
HDX difference measurements at 1.54s comparing holoenzyme TEM-1 to TEM-1 exposed to 
saturating concentrations of ampicillin, cephalexin and clavulanate (from top to bottom). Positive 
(red) bars indicate increased uptake relative to the free protein and negative (blue) bars denote 
decreased uptake relative to the free protein. Right: Peptides with significant changes (> 2, n=9) are 
displayed on the crystal structure, PBD ID: 1BTL using the same colour scheme (with the addition of 
gold = no change, grey = unobserved). 
 
With ampicillin-incubated TEM-1 there are regions of both increased and decreased deuterium 
uptake with catalytic turnover, with exclusive dynamics within the S3-S5 β-sheets and rigidification 
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of H3 and S1. As ampicillin is the only substrate under study with rapid hydrolysis by TEM-1, we can 
isolate changes in dynamics that are exclusive to the ampicillin profile as being linked to efficient 
deacylation.  The same logic is applied to the other two substrates and their interaction with TEM-1. 
For the profile with cephalexin (fig 2.3, middle), we correlate the known behaviour of inefficient 
hydrolysis to the unique changes in deuterium uptake, such as increased dynamics in the H3/H4 loop, 
S4 and the S4/S5 loop. These key regions are known to contain mutational sites and salt bridges of 
importance for protein stability, inferring that inefficient deacylation is associated with increased 
flexibility.  If comparing ampicillin and cephalexin HDX profiles, it is possible to distinguish further 
regions that participate in deacylation, but with differing intensities, such as H3/H4 loop where 
ampicillin has an increase in uptake and cephalexin decreases. For clavulanate, changes in uptake 
that correspond to a unique dynamic profile (relative to cephalexin and ampicillin) can be linked to 
deacylation failure. Additionally, regions of increased dynamics that are exclusive to cephalexin and 
ampicillin can also be inferred as being involved in the hydrolysis of the acyl-enzyme (such as H8 and 
S3/S4 increases in uptake). Finally, for regions that behave similarly with all 3 substrates, we can infer 
that they must be involved in the binding process of substrate hydrolysis.  
Although conventional HDX may be able to offer a global overview of perturbations to the hydrogen 
backbone of a protein, the dynamics associated with capturing transient intermediates or relative 
rates of each mechanistic process are best observed on the ms timescale. By using TRESI-HDX, we 
have been able to identify different regions of interest in the TEM-1 hydrolysis of ampicillin, 
cephalexin or clavulanate, and correlate these regions to specific functional roles in the hydrolysis of 
the substrate.  
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2.3.3 Backbone Dynamics of TEM-1 during Binding 
As binding is the only mechanistic process in which all 3 substrates are known to behave similarly 
(due to kinetic studies and structural similarities), regions with dynamic modes associated with 
binding should exhibit similar (within 2σ) uptake profiles. The first region that matched these criteria 
was residues 70-73 (N-terminus of H2), well-known as the conserved SXXK motif responsible for the 
Ser70 binding site in all Class A β-lactamases.  All substrate-bound TEM-1 complexes exhibit a 
decrease in dynamics relative to the apo-enzyme (figure 2.4, top), with approximately 25% less 
uptake than unbound TEM-1. This suggest a single amide bond suppression of dynamics or 
inaccessibility of exchange, either due to binding of the substrate or a conformational change that 
generated new hydrogen bonding within the active site. Although there is no crystallographic 
evidence for the direct binding of clavulanate within the active site, it is possible that rearrangement 
of the backbone amides with incubation generated a hydrogen-bond link between Ser70 and 
Lys73144.  
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Figure 2.4 Kinetic Deuterium Uptake for Binding Dynamics of TEM-1.TRESI-HDX kinetics plots for 
dynamics of binding (top, residues 70-73; and bottom, residues 225-232) are displayed for each drug 
product (ampicillin, red; cephalexin, green; clavulanate, blue) for comparison to the unbound TEM-
1 profile (black line) (1, n=9). Crystal structures to the right display the relevant peptide fragment 
in pink, with nearby residues of importance highlighted in teal.  
 
Another region, residues 225-232, also exhibits a decrease in deuterium uptake with all three 
substrates (fig 2.4, bottom). Corresponding to the H10/S3 loop, this region is part of a larger section 
of the protein recently discovered as an allosteric binding site197. Interestingly, inhibitors that have 
been known to bind within this region are productive because they are able to physically separate 
H11 and H10, suggesting that decreased dynamics between these helices is necessary for catalysis 
to occur. Known residues of high mutational activity are sequentially very close to this region: Ser235 
is of importance for cephalosporin resistance, and Lys234 is necessary for hydrogen bonding of 
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incoming substrate into the active site183. With known evidence of surrounding residue involvement 
in binding and stability of the protein, our observations agree well with the idea that decreased 
dynamics in residues 225-232 are linked to substrate binding.  
 
2.3.4 Backbone Dynamics of TEM-1 during Productive Acylation 
 
Productive acylation refers to the successful process of acylation of the β-lactam core followed by 
hydrolysis of the complete small molecule, which is carried out efficiently with ampicillin-bound TEM-
1, and slowly with cephalexin-bound TEM-1. Since both ampicillin and cephalexin are hydrolyzed by 
TEM-1, they should exhibit similar dynamics profiles for deuterium uptake and be significantly 
different than the clavulanate profile, allowing us to isolate regions that are exclusive to clavulanate 
activity. Residues 240-247 (fig 2.5, top) demonstrates a minor increase in deuterium uptake with 
acylation occurring, and a significant decrease in uptake when acylation does not. Within this region 
is the critically important Arg244, known for forming salt bridges and ionic bonds responsible for 
stabilizing protein structure through tethering of substrate carboxylate group during acylation198. 
This region gives direct evidence of the difference in turnover rates of each substrate, as the 
ampicillin profile shows a rapid and high amplitude of deuterium uptake, which can be linked to more 
intense dynamics and a greater number of exchangeable sites on the timescale as observed with 
rapid turnover85. In contrast, cephalexin has a slower increase in deuterium uptake, but eventually 
demonstrates the same overall rate for uptake as ampicillin. This is likely due to the slower and 
complete turnover of cephalexin (𝑘𝑐𝑎𝑡 = 13 ± 1 𝑠
−1)199, which requires multiple turnover events to 
achieve maximum deuteration.  
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Figure 2.5 Kinetic Deuterium Uptake for Acylation and Deacylation Dynamics of TEM-1.  TRESI-HDX 
kinetics plots for dynamics of productive acylation (top, residues 240-247) and slow deacylation 
(bottom, residues 111-114) are displayed for each drug product (ampicillin, red; cephalexin, green; 
clavulanate, blue) for comparison to the unbound TEM-1 profile (black line) (1, n=9). Crystal 
structures to the right displays the relevant fragment in pink, with nearby residues of importance 
highlighted in teal. The exact uptake at 111-114 in Clavulanate-bound TEM-1 was not recovered 
during experimentation, however the region is depicted in overlapping fragments showing minimal 
change relative to the unbound TEM-1 (shown in figure 2.3).  
 
For clavulanate, we observe a noticeable decrease in deuterium uptake on this timescale, with at 
least one residue becoming inaccessible for exchange. Since Arg244 is known to have complexation 
with the carboxylate group of the incoming clavulanate during binding200, reduced deuterium uptake 
in this region is associated with deacylation failure.   
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2.3.5 Backbone Dynamics of TEM-1 during Slow Deacylation 
Slow deacylation dynamics are exclusive to cephalexin and cephalosporin-family drugs for these 
experiments. Cephalosporins are known to have increased potency over first-generation penicillins 
due to their slower turnover and decreased deacylation from the binding site183. Therefore, changes 
in dynamics observed by TRESI-HDX that are exclusive to cephalexin are associated with the 
inefficient hydrolysis of the acyl-enzyme. In figure 2.5 (bottom), residues 111-114 of the H3/H4 loop 
are depicted.  Within this region is the highly mutational residue Lys111, which has increased 
mutational frequency and resistance in the presence of cephalosporins (specifically cefotaxime)201. 
This link between cephalosporin resistance at K111 and our kinetic workflow must be taken with a 
grain of salt, as we cannot measure deuterium exchange at the N-terminal residue of peptides72.  
Another region that corresponds to the above criteria for slow deacylation is residues 245-257, 
corresponding to the S4/S5 loop. This region is depicted in figure 2.3 as having unique dynamics to 
cephalexin, but unfortunately was not recorded in triplicate for all substrate runs in order to generate 
kinetic plots. However, partially overlapping regions such as 240-247 and 250-257 suggest that 
increased deuterium uptake is unique to the cephalexin trials. As mentioned earlier, regions known 
to evolve mutations as part of cephalosporin resistance such as Arg 244 are identified within this 
region (Ile247, Ala249, Asp254, Lys256)201, potentially demonstrating that additional flexibility within 
this region for substrate hydrolysis is necessary. This region should be further targeted for 
development of co-inhibitors to limit cephalosporin resistance by rigidifying the 245-257 region.  
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2.3.6 Backbone Dynamics of TEM-1 during Deacylation Failure 
Only the clavulanate substrate has an inhibitory effect on TEM-1 for this study, as such, changes in 
dynamics that are exclusive to clavulanate binding can be linked to a failure to deacylate from the 
binding site. One region identified as showing a unique and significant decrease in deuterium uptake 
is residues 250-257 (fig 2.6, top), which corresponds to the S4/S5 loop of TEM-1. These results agree 
with our previous discussion of the S4/S5 loop involvement in cephalosporin activity (for residues 
245-257). We suggest that dynamics within 250-257 are linked to deacylation, with variation 
depending on the family of drug used: high flexibility/dynamics for hydrolysis of bulkier substrates 
(cephalexin), moderate flexibility for smaller substrates (ampicillin) and lowered 
flexibility/rigidification for deacylation failure (clavulanate).  
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Figure 2.6 Kinetic Deuterium Uptake for Inhibition Dynamics of TEM-1. TRESI-HDX kinetics plots for 
dynamics of deacylation failure (top, residues 250-257; middle, 274-276; bottom, 280-284) are 
displayed for each drug product (ampicillin, red; cephalexin, green; clavulanate, blue) for comparison 
to the unbound TEM-1 profile (black line) (1, n=9). In residues 280-284, cephalexin does not have a 
statistically significant decrease (> 2) relative to the unbound TEM-1. Crystal structures to the right 
displays the relevant fragment in pink, with nearby residues of importance highlighted in teal.  
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Residues 273-284 (fig 2.6, middle and bottom) all correspond to the C-terminal helix (H11), 
substantially distant from the active site. However, there are a number of high mutational frequency 
site contained within this region, such as Arg275 and Asn276, highly associated with resistance to 
inactivation by clavulanate via displacement of the water molecule involved in the inactivation 
pathway, or through interactions with Arg244202. Asn276 mutational studies have also provided a 
demonstration of decreased catalytic efficiency with mutations at this residue,  and higher Ki for 
clavulanate, demonstrating further evidence of the importance of H11 interactions and the active 
site202. Residues 280-284 (fig 2.6, bottom) correspond to the allosteric inhibitor site discussed 
previously at the interface of H10/S3. Residues 280-284 have a decreased and similar uptakes for 
cephalexin and clavulanate, with much slower uptake kinetics exhibited by cephalexin. 
 
2.4 Conclusion 
TEM-1 has been the principal β-lactamase under study for decades, providing a wide variety of 
mutational residue analysis and kinetic characterization of a variety of drug substrates and 
inhibitors203,204. Along with sequence-specific analysis, there are a large amount of NMR and X-ray 
structures that can help provide structure/function relationships. With all of this in-depth structural 
knowledge, TEM-1 is an ideal system for implementing TRESI-HDX to provide insight into the 
mechanistic implications of each drug family as studied under fast reaction conditions. Although HDX 
does require a basic crystal structure to guide the mapping of dynamics, it is a highly sensitive tool 
for determining changes in conformational dynamics due to the presence of a substrate or inhibitor. 
Herein we demonstrate how TRESI-HDX can be used to compare apo and holo-enzyme forms of TEM-
1 β-lactamase in terms of changes in dynamics, not structure. From this, we have identified regions 
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with dynamics linked to specific mechanistic processes as a means of isolating catalytically important 
residues for drug development. Based on the results discussed above, two regions have been 
mentioned more than once as important in substrate resistance and catalysis: residues 250-257 
(S4/S5 loop) and residues 273-284 (H11). Residues 250-257 are linked to cephalosporin-family 
resistance, with varying levels of dynamics responsible for differing substrate binding. Results herein 
demonstrate that moderate rigidification of this region by a co-inhibitor would sensitize TEM-1 to 
cephalosporins (instead of penicillins), renewing their potency and providing a longer shelf life for 
current on-the-market cephalosporins, such as cephalexin.  Residues 273-284 have been discussed 
above as potentially being involved in the docking of allosteric inhibitors through rigidification of this 
region205–207; work by Horn197 has demonstrated that this region contains a small molecule binding 
site that operates independently of the SXXK motif. Our results have shown that turnover can be 
related to the degree of flexibility in H11, and rigidification with an inhibitor bound may be key to 
inhibiting catalysis98,197. This approach of millisecond-scale HDX is well-suited for studying various 
catalytic systems that have turnover events within the observable timescale, especially for studying 
protein systems where there is limited structural or biochemical information known to provide a link 
between enzyme catalysis and conformational dynamics208–211.  
 
2.5 Methods 
Reagents 
All chemicals were purchased from Sigma Aldrich. Buffer solutions and water used was generated in 
lab using a Millipore Milli-Q Advantage A10 system.  
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2.5.1 Expression and Purification of TEM-1 β-lactamase 
TEM-1 β-lactamase with a SpyTag/SpyCatcher tag was purchased from AddGene (plasmid #52656, 
pET28a vector). Plasmids were extracted from the DH5α cell line into competent BL21 (DE3) cells. 
Cells were expressed in LB broth with 50mg/mL Kanamycin and 1M glucose. 1M IPTG was added 
once log phase absorption was reached (A600=0.5-0.7). The culture was incubated at 18oC for 16 
hours at 200 rpm before centrifugation (6000g, 15 minutes, rotor JA 25.1). The pellet was 
resuspended with 1mM PMSF (120 μL) and 1mM protease inhibitor (120 μL) with Ni-NTA binding 
buffer (12 mL, 50mM Tris and 300 mM NaCl, pH 7.8). The cell solution was lysed using a Fisher 
Scientific Sonic Demembrator Model 500 and then centrifuged. Protein was eluted on a Ni(2+) 
sepharose resin column with 75mM Imidazole and buffer exchanged in 250mM ammonium acetate 
(pH 6.7) for at minimum 36 hrs prior to evaluating protein concentration. BCA assays and SDS-PAGE 
analysis were performed to determine protein concentration.   
 
2.5.2 Digest Preparation 
Protease XIII or Pepsin protein with NHS activated agarose (2:5 w/w) was suspended in coupling 
buffer (0.1M sodium phosphate and 0.15M NaCl, pH 5.5) and rotated overnight at 40C.  The aspirated 
protease was then suspended in 1M Tris-HCl blocking buffer (pH 5) and rotated at room temperature 
for 1 hour. The beads were washed three times with acetic acid (pH 2.4) and stored at 40C to be used 
in subsequent runs.  
2.5.3 Chip Design 
Previous chip designs by our lab have been discussed212,213 that formed a digestion well by using a 
plastic seal over PMMA plates and were clamped using a customized holder. The chip was designed 
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in lab using a VersaLaser™ to etch a well into a PMMA plate measuring 5.1cmx2.0cmx1.2cm. A newer 
chip design was generated using the CorelDrawx3 program. The well was cleaned with methanol and 
etching was repeated. The procedure is then repeated with an identically sized PMMA plate. The 
paper backing on each plate was removed, with plates then being lined up together to generate a 
well between the chips. Capillaries were left at opposite ends to provide channels into the well while 
the two plates were clamped together. A needled bottle containing acrylic weld was inserted into 
the middle of the well and acrylic was dispensed until edges were sealed. The solution set for 1 
minute before removing the capillaries. A needle was inserted into the well for aeration of the chip. 
The chip was dried for 48 hours, then bored into by a drill press using the 10-32 NF bit. The depth 
was set to 9 mm. The chip was drilled from both ends, using a methanol rinse throughout. Excess 
plastic caught inside the well was removed with a needle. A 10-32 NF bottoming tap was manually 
inserted into both ends of the chip to add the threads. The inside of the chip was washed with water 
to ensure all debris was removed. Acrylic weld was flowed through the well and excess was tapped 
out immediately. The chip was dried for another 48 hours. A 33-gauge stainless steel metal capillary 
was cut into two pieces with a rotary tool (with each piece being approximately 10 cm long) and 
sanded to smooth the ends. The metal capillaries were added as input and output channels on the 
chip by screwing into the ends via double-winged nuts.  
 
2.5.4 Microfluidics Workflow 
The 28-gauge metal capillary of the TRESI mixer had an inner diametre of 178.8 μm, while the glass 
capillary inserted within had an outer diameter of 151 μm. The protein flowed into the device at 3 
μL/min, as did the deuterium and substrate capillary. The acid was introduced at a rate of 12 μL/min. 
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The protein and deuterium mixtures join in the intercapillary space before reaching the tri-union, 
where acid quenches the hydrogen exchange and limits it to backbone amide hydrogens. The volume 
of intercapillary space for deuterium incubation can be altered to give time-dependent incubating 
results by adjusting the inner glass capillary position in relation to the outer metal capillary. The 
quenched protein is then digested in the PMMA well (containing the proteolytic digest described 
above) before being sprayed into the Synapt G1 Time-of-Flight  (ToF) instrument with a source 
voltage of 2700 V in positive ion mode.  
 
2.5.5 Data Analysis 
ESI-MS data was obtained in the 350-1500 m/z range. A 250mM ammonium acetate solution (pH 
6.7) was used to buffer exchange TEM-1 prior to experimentation. A 10:1 TEM-1: substrate ratio was 
used to ensure the reaction could still be monitored by ESI after the time taken for solutions to 
incubate in the capillaries. Experiments were run in triplicate each day for every enzyme/substrate 
combination, with deuterium uptake per peptide being averaged over matching peptides from a 
biological replicate (n=9). Multiple purifications of TEM-1 were performed and similar results for 
matching peptides were obtained, with significant differences referring to a confidence interval of 
95% (2). Peptides were identified using ExPASY Proteomics. MS/MS analysis was performed in V-
mode to confirm the peptide identity (using mMass) before complete uptake analysis by manually 
ramping the trap collision energy from 30 to 50 V, having a 1 second scan time and recording in the 
100-2000 Da range. Deuterium uptake per peptide was calculated using in-house FORTRAN software 
that matches the experimental uptake to the predicted isotopic distribution for the native peptides.  
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Chapter 3 
Collision-Induced Unfolding and Hydrogen/Deuterium 
Exchange Mass Spectrometry as Tools for Comparing 
Binding Affinity of TEM-1 β-lactamase Inhibitors 
 
 
 
 
A version of this chapter has been prepared in manuscript format.  
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3.1 Summary 
 
Inhibition pathways in β-lactamases are of increasing interest in the medicinal community with 
antibiotic resistance on the rise. By examining the binding affinity of all current class A β-
lactamase inhibitors through a variety of techniques, including local HDX and CIU-MS, we were 
able to identify the inhibited residues for the enzyme: substrate complexes, depending on 
concentration of substrate during incubation. With a substantial inhibitor: enzyme ratio of 
1000:1, binding is observed after 10 minutes of incubation, with tazobactam-incubated TEM-1 
demonstrating complete inactivation and formation of a +52Da byproduct after 60 minutes at the 
Ser70 residue.  With a lower ratio of 10:1, sulbactam and tazobactam samples demonstrate late-
onset binding and eventual inhibition of the Ser130 residue, in contrast to the 1000:1 inhibitor 
concentration.  Specific residue regions (70-73, 161-179, 220-251, 270-284) have been identified 
as the most crucial for substrate inhibition for clavulanate, sulbactam and tazobactam. 
 
3.2 Introduction 
TEM-1 β-lactamase is an enzyme generated in predominantly gram-negative bacteria as an 
evolutionary step to hydrolyze antibiotics, most of which contain a β-lactam core97,98,124,203. In 
response to the increasing futility of employing β-lactam core drugs, inhibitory drugs were 
developed in the early 1970s as a supplement to β-lactam drugs in the hopes they would reduce 
resistance to the original drug substance. Through covalent binding to the active site of TEM-1, 
inhibition byproducts are produced that are cleaved fragments of the original substrate 
(originating from the leaving group on C-5 of the 5-membered rings)112,195. The inhibitory drugs 
on the market (used in conjunction with β-lactam drugs) are clavulanate, tazobactam and 
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sulbactam, each with unique reactivities120,187. Clavulanate (produced in the 1970s) is the most 
common and most potent β-lactamase inhibitor214 in Class A β-lactamases when taken with 
penicillins (as determined by IC50 results and Ki values)215, but is much weaker than the sulfonated 
products sulbactam and tazobactam when paired with cephalosporins195,216,217(such as 
cephalexin, a drug studied in previous publication55). Along with a limited amount of inhibitory β-
lactam drugs on the market, little is mentioned about the byproducts of enzyme inactivation 
produced by each inhibitor and how this affects the rate of inhibition of different β-
lactamases218,219. The inhibitors inactivate through a series of off-pathway intermediates, thought 
to covalently cross-link a serine residue (Ser130) to the active site (Ser70) after a series of imine-
enamine conversions (figure 3.1)194,202,215,220–222. The resulting fragmented alkyl chain would be 
permanently bound to a residue within the active site, inhibiting substrate hydrolysis of incoming 
drug substrate. Peptide-level Hydrogen/Deuterium Exchange mass spectrometry (HDX-MS) is an 
ideal technique to confirm the specific residues involved in permanent deactivation of the active 
site and determine if these residues are unique to the inhibiting substrate. By using a novel 
microfluidics apparatus, it is possible to observe the enzyme inactivation in a time-resolved 
fashion223. These results at a local level can be paired with more global protein structure 
determination by mass spectrometry, such as collision-induced unfolding (CIU). CIU is a relatively 
new technique used in analytical and medicinal mass spectrometry to provide evidence of 
comparative binding affinity between protein substrates45–48. The protein sample is bombarded 
with neutral gas at increasing voltages to encourage intermolecular collisions, with weakly-bound 
proteins unfolding at a lower voltage than strongly bound substrate. Protein unfolding is captured 
using ion-mobility mass spectrometry (IMS-MS)32,33 which measures the collisional cross-section 
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and drift time of all ions passing through the IMS cell, and can distinguish them by size, shape and 
stability39,40. This practice is paired with protein-ligand binding to provide a comparison of binding 
affinity between ligands or drug substrates and the tertiary structure45,224,225.  Given the stability 
and prevalence of TEM-1 in the global microbial population, it is an ideal target for a 
combinatorial study using these techniques. We postulate that using HDX in conjunction with 
time-resolved HDX-MS226  and CIU will provide a more comprehensive analysis of the three 
inhibitory drugs currently on the market and provide further evidence for the differences in 
mechanistic pathways and binding affinity. This is turn will help direct synthetic chemists to more 
optimal structures that will provide greater binding affinity and inhibition against TEM-1 and 
related Class A β-lactamases. 
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Figure 3.1 TEM-1 Inhibitors and Potential Fragmentation Products. Chemical structures of TEM-1 
inhibitors, along with potential inhibition fragments generated and isomerization of the sulbactam 
hydrolysis pathway. From the most common fragmentations shown above, it is clear that hydrolysis 
of substrate generates a limited amount of mass variation. Peptide-level mass spectrometry using 
HDX allows us to observe local binding and distinguish which serine residues are ultimately 
responsible for inactivation. 
 
3.3 Results 
On the market inhibitors irreversibly inactivate TEM-1 (and various other β-lactamases) through 
covalent bonding at varying concentrations, with tazobactam and clavulanate having similar potency 
compared to a much weaker sulbactam in in vivo studies215. Surprisingly, having an excessive ratio of 
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inhibitor to protein involved in the inactivation of TEM-1 has be known to produce lower rates of 
inactivation than expected120,220,227 and having drastically different ratios in inhibitor to enzyme 
incubation has previously resulted in changes in intermediates formed for many β-lactamases228. We 
sought to correlate assay binding affinity results (for a fixed inhibitor concentration) to byproduct 
generation (and the favoured mechanistic pathway) of each irreversible inhibitor by multiple types 
of experiments. By incubating the samples with molar concentrations of 10:1 and 1000:1 inhibitor: 
enzyme, we seek to compare mass spectrometry results to in vivo studies (Sulbactam, Ki=0.9 µM; 
Clavulanate and Tazobactam, Ki=0.1 µM)215 and determine if different inhibitory products are 
apparent with greater enzyme saturation. 
 
3.3.1 Measuring Inhibitor Byproduct Formation by Mass Spectrometry 
Before looking at the binding affinity results by collision induced unfolding (CIU) of the protein: 
substrate complex, the native mass spectrometry must show effective binding at both concentrations 
of inhibitor: enzyme. Products formed during the inhibitory pathway must then be identified to 
determine how the CIU relative binding affinity data can compare. Several scans of native mass 
spectrometry were used to determine the onset of substrate binding and degradation products (and 
potentially a complete reversal to unbound TEM-1); every 10, 30, 60, 120 and 240-minutes mass 
spectra were recorded at both concentrations, taking the centroid mass. Below in figure 3.2, our 
results with the 10:1 inhibitor to enzyme ratio (magnified at the +21 charge state) are shown to 
demonstrate the sensitivity to binding that can be observed before 60 minutes have passed, unlike a 
single time point trial under pharmaceutical study220.  
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Figure 3.2 Native Mass Spectrometry Inhibitor Binding Study With 1000:1 Ratio Above) Native mass 
spectrometry of TEM-1 incubated with substrates over 5 time points. +21 charge state is highlighted 
in green for magnification below. TEM-1 incubation at 5 time points is displayed with the following 
colours: 10 mins (green), 30 mins (light orange), 60 mins (pale blue), 120 mins (dark orange) and 240 
mins (light green). All experiments were run in triplicate and all drug substrates were incubated and 
mass spectra taken on the same day. Protein concentration was confirmed by BCA Assay prior to 
experimentation.  In blue, the unbound +21 peak (at 2180 m/z) is highlighted. Bottom) Inset into the 
native spectra for each incubation are potential cross-linking inhibitor fragments associated with the 
mass increases listed. 
 
To confirm byproducts intermediates were not overlooked prior to 10 minutes of incubation, scans 
were also recorded at 1,3,5,7 and 9 minutes with no additional binding observed (see Appendix B). 
It is apparent that with the larger inhibitor concentration of 1000:1 (figure 3.2), we see a large mass 
increase occurring by the time the first spectra (green line) is recorded at 10 minutes (clavulanate, 
+261 Da; sulbactam, +317 Da; tazobactam, +368 Da), of greater mass than the substrate alone. Both 
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clavulanate and tazobactam samples have a mass increase corresponding to a sodium or acetate 
adduct, respectively. The sulbactam spectra was consistently less resolved than the other two drugs- 
this is likely due to the weaker binding affinity and inability to form permanent acyl-enzyme 
products202,215. For the clavulanate and sulbactam samples this mass increases with time, likely due 
to multiple adduct formation. In contrast with sulbactam, the chemically similar tazobactam 
experiment records a mass shift associated with drug binding and an acetate adduct at 10 minutes, 
then changes to a lower mass product at 60 minutes which becomes the dominant product by 120 
minutes. This byproduct seen after 60 mins of incubation (+52Da) has been postulated before as a 
propynyl chain, seen in figure 3.1, far left, bound to Ser70220. This lower mass byproduct is what we 
would expect from the inhibitor binding- as the drug is partially hydrolyzed, a fragment of the 
substrate remains in the drug pocket to inhibit further hydrolysis via the serine 70 residue194,195,216. 
To confirm the propynyl (Ser70) or cross-linked product (Ser70 and Ser130) associated with the +52Da 
increase, local HDX results will provide more insight. 
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Figure 3.3 Native Mass Spectrometry Inhibitor Binding Study With 10:1 Ratio Above) Native mass 
spectrometry of TEM-1 incubated with substrates over 5 time points. +21 charge state is highlighted 
in green for magnification below. TEM-1 incubation at 5 time points is displayed with the following 
colours: 10 mins (green), 30 mins (light orange), 60 mins (pale blue), 120 mins (dark orange) and 240 
mins (light green). All experiments were run in triplicate and all drug substrates were incubated and 
mass spectra taken on the same day. Protein concentration was confirmed by BCA Assay prior to 
experimentation.  In blue, the unbound +21 peak (at 2180 m/z) is highlighted. Bottom) Inset into the 
native spectra for each incubation are potential cross-linking inhibitor fragments associated with the 
mass increases listed. 
 
Results at the lower 10:1 ratio (figure 3.3) prove more interesting. At this much smaller ratio, 
clavulanate is not present to inhibit the complete population binding (+170Da), and instead has the 
addition of a sodium molecule within the binding pocket after 60 minutes (+22Da).  Sulbactam and 
tazobactam behave more similarly on the hours timescale, which could be due to their similarly 
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sulfonated structures that has increased stabilization within the binding pocket. Sulbactam shows no 
evidence of binding until 120 minutes (+70Da), with tazobactam showing complete binding at 10 
minutes and reversion to the same byproduct (+70Da) as sulbactam after 120 minutes. Others have 
previously reported on an adduct of +40Da forming with both sulbactam and tazobactam in a class C 
β-lactamase228, suggesting very similar mechanistic pathways in all serine-catalyzed β-lactamases 
inhibited by sulfones.  The similar binding product mass at 120 minutes discovered in both sulfonated 
substrate experiments suggests the same mass byproduct formation, likely being the +70Da product 
of an aldehyde byproduct covalently linked to Ser70 discovered in previous work220,229. Although the 
byproducts are the same mass, they may operate through two different mechanistic pathways 
because of their residues involved: the substrate product forming slowly after two hours (with 
sulbactam incubation) is most likely permanent inactivation, binding to Ser70. The tazobactam 
product of +70Da may also be part of an irreversible inactivation pathway, but potentially binding to 
the other important serine residue,  Ser130138,227. Further analysis at the peptide level for binding will 
provide conclusive binding results.  
 
3.3.2 Local HDX Coverage of TEM-1 β-lactamase  
To help visualize the regions of the protein involved in long-term inhibition, local HDX was carried out 
in biological replicate at several time points. Based on the binding affinity results described above, 
we continued the study with a 10-minute incubation time for the 1000:1 ratio which should give 
complete residue information after TEM-1 has become inhibited with all substrates.    
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Figure 3.4 Local Deuterium Uptake Results for Equilibrated HDX-MS with Inhibitors in 1000:1 
Inhibitor: Enzyme Ratio. Left: Difference in deuterium uptake between TEM-1 and incubated TEM-1 
with substrate is displayed for the 1000:1 inhibitor: enzyme ratio. Peptide fragments in colour (blue, 
decreasing; red, increasing; grey, no change) signify differences in deuterium uptake between the 
holo and apo enzyme forms (>2σ, dotted black line). Right: Pymol image (PBD ID: 1BTL) displays the 
significant changes in dynamics for all substrates (top, clavulanate; middle, sulbactam; bottom, 
tazobactam). Regions on the structure with no significant change are displayed in gold, increasing in 
red, decreasing in blue and unrecorded regions are in grey. 
 
Unsurprisingly with the 1000:1 inhibitor incubation, the deuterium uptake was reduced upon mixing 
with the inhibitors relative to the unbound protein sample (figure 3.4), suggesting a rigidification of 
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the overall structure that is common with inhibiting products. The tazobactam-incubated sample 
provided the most consistent decrease in conformational dynamics both sequentially and spatially, 
with the inner β-sheets (responsible for stability through salt bridges and covalent bonding within 
the binding site113,124,203) and binding region (residues 70-73) showing uniform rigidification. The 
sulbactam-incubated sample had a high degree of flexibility, providing a limited amount of significant 
changes in deuterium uptake. However, there is a consistent pattern of rigidification in H11 (residues 
270-284) across all samples that we postulated before is necessary for complete enzyme 
inactivation55. The clavulanate sample has one unique region with increased dynamics (residues 144-
147) that has not been previously described as important for catalytic binding or as a potential for 
mutagenesis201, but otherwise has similar rigidification patterns to sulbactam and clavulanate. 
 
In stark contrast with the consistent rigidification and inhibition results displayed in figure 3.4, the 
lower ratio of 10:1 inhibitor: enzyme was too little substrate to completely initiate the inactivation 
pathway in TEM-1 (on average) within this time frame. With a longer timescale of 120 mins incubation 
of the 10:1 inhibitor: enzyme samples, protein was not soluble enough to carry out local HDX 
workflow without extensive aggregation (likely due to the inactivated protein). 
 
3.3.3 Comparison of Inhibitor Binding Affinity by Collision Induced Unfolding -Mass Spectrometry 
Collision-induced unfolding (CIU) with intact protein/substrate complexes can supplement local HDX 
analysis of peptides that has difficulties with a large error range based on artificial deflation of 
deuterium uptake generated by peptide bombardment in the collision cell230. We can also observe 
changes in stability upon inhibitor binding based on the unfolding map provided40,45. To utilize CIU in 
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conjunction with HDX, we analyze TEM-1 as an intact protein (for binding and unfolding studies) and 
through bottom-up proteomics (for HDX of peptides). A detailed representation of the workflow is 
displayed in figure 3.5.   
 
Figure 3.5 Local HDX Workflow for TRESI-HDX and IMS-MS Experiments. Top) For our bottom-up 
proteomics (TRESI HDX-MS), protein and deuterium capillaries react at a fixed distance (measured by 
pulling out the inner capillary) before the reaction is quenched by acetic acid (pH 2.4). The deuterated 
sample is then digested within a PMMA chip by protease XVIII and pepsin. With IMS-enabled 
experiments, the TriWave component of the Synapt separates the sample (whole proteins for CIU 
studies, peptides for HDX) by collisional cross section (CCS) based on drift time. Bottom) The crystal 
structure of TEM-1 (PBD ID: 1BTL) is shown on the left with secondary structure noted. On the right, 
the HDX results for TEM-1 reacted with Tazobactam are displayed. Blue regions indicate a decrease 
in dynamics, grey is no coverage and gold indicated no change (with respect to the unbound protein 
sample).   
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To determine the initial ramping and binding conditions, several rounds of optimization were 
performed. Complete binding and formation of the acyl-enzyme was uniformly observed after 10 
minutes of incubation with the 1000:1 ratio, but all substrates demonstrated differing binding 
activities after 30 minutes, so all results for binding affinity were recorded within this timeframe. The 
10:1 ratio experiment were also recorded after 10 minutes to determine if there was binding activity 
observed that was not observed by native mass spectrometry. A travelling-wave velocity of 400 m/s 
produced the best resolution of bound protein without causing pre-fragmentation of the samples. 
 
 
Figure 3.6 CIU Heat Maps of Binding Affinity for TEM-1 and Inhibitors with a 1000:1 Ratio of 
Inhibitor to TEM-1. CIU spectra of inhibitor-bound TEM-1 for the 1000:1 experiment at collisional 
voltages from 0-100 V, taken in 5V increments. All spectra were recorded for the +16-charge state.  
 
Upon initial inspection of the results in figure 3.6, it is apparent that the clavulanate sample at the 
1000:1 ratio produces the most distinct transitions between folding states and completes the final 
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(third) transition to a more unfolded conformation at the highest collisional energy (~70 V). 
Tazobactam and sulbactam samples both unfold at nearly identical rates to each other and to the 
unbound TEM-1, with two transitions occurring below 50 V. Having the clavam inhibitor produce 
unique results with higher binding affinity can be explained structurally; the lack of a sulfone leaving 
group on the five-membered ring means the compound is not easily protonated for the ring opening, 
leading to the subsequent β-elimination occurring at a higher binding energy195,215. Surprisingly, the 
clavulanate-bound sample is also much more destabilizing, as noted by the higher arrival times. This 
suggests that the sulfonated byproducts force the protein into a more compact form, regardless of 
the additional molecular weight associated with the sulfone group and the presence of the triazole 
component of tazobactam. 
 
Figure 3.7 CIU Heat Maps of Binding Affinity for TEM-1 and Inhibitors with a 10:1 Ratio of Inhibitor 
to TEM-1. CIU spectra of inhibitor-bound TEM-1 for the 10:1 experiment at collisional voltages from 
0-100 V, taken in 5V increments. All spectra were recorded for the +16-charge state.  
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For the 10:1 CIU spectra shown in figure 3.7, the similarity between incubated samples and unbound 
TEM-1 suggest a lack of binding. For all 3 inhibitor spectra, there is a similar unfolding pattern, with 
2 conformational changes occurring before 50 V. What is most interesting about these results are the 
lack of a third unfolding state in the first 50 V as observed with the unbound protein, suggesting that 
the presence of a minute amount of inhibitor in solution may slightly stabilize the encompassing 
protein sample.  
 
3.4 Discussion  
It is difficult to draw conclusive statements regarding the potency of each inhibitor under study 
without a degree of caution. Although the CIU results would suggest that clavulanate provides the 
tightest binding affinity with a ratio of 1000:1, there are fewer regions of increased rigidity in TEM-1 
upon binding in our HDX results when compared to tazobactam. Tazobactam-bound TEM-1 provides 
the most “locked in” conformation, but mass shift results from native binding studies have 
conclusively demonstrated binding of all substrates at the higher molar ratio, so this binding behavior 
is not unique to tazobactam.  Perhaps having fewer regions of rigidification with clavulanate-HDX 
instead brings to light the regions that are in fact the most important for binding; the conserved 
binding site (residues 70-73), two inner β-sheets (residues 220-251), the Ω-loop (residues 161-179) 
and α-helix H11 (residues 270-284) are the only regions that are significantly rigidified upon 
clavulanate binding, in agreement with the current understanding of substrate binding to Class A β -
lactmases203,231–233. The additional rigidification noted in the tazobactam sample could be allosteric 
effects induced post binding, as they are not present in the uptake on the ms-timescale.  Although 
sulbactam and tazobactam display near-identical collisional unfolding results at the 1000:1 and 10:1 
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ratios, the HDX results show limited changes in dynamics relative to unbound protein at the binding 
site and Ω-loop for the sulbactam sample on the short timescale, likely due to sulbactam’s weak 
binding affinity.  
 
Questions pertaining to binding affinity may be better answered by discussing the observed mass 
shifts. In both binding studies, the final +52Da (1000:1) and +70Da (10:1) products produced by the 
tazobactam incubation are likely bound to a serine residue. However, for the tazobactam 
experiments, Ser70 was bound in the 1000:1 experiment while Ser130 was bound in the 10:1 study. 
This +52Da sample was likely the final inhibitory byproduct formed by tazobactam in high saturating 
conditions, while +70Da connection to Ser130 is more prevalent at low dosage. With the larger 
inhibitory ratio, clavulanate and sulbactam exist in an acyl-enzyme form without generating an 
inhibiting fragment to permanently block the active site.  Sulbactam has never been noted to exhibit 
slow-onset inhibition229, and this is especially unexpected at a low inhibitory ratio. Yet in the 10:1 
study, there is the formation of an intermediate that is postulated to bind at the Ser130 residue 
responsible for drug deacylation, causing a permanent inactivation of TEM-1 in the binding pocket. 
By recording native scans at such large time intervals, we did not believe it would be possible to 
observe mechanistic differences in the permanent vs transient inactivation pathways. 
 
3.5 Conclusions 
Using different inhibitory ratios provided an opportunity to observe changes in the mechanistic 
pathway of the inactivation of TEM-1 by several inhibitors, such as the production of two different 
inactivation byproducts with tazobactam incubation at different concentrations, and the production 
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of an inhibited enzyme by low concentration of sulbactam incubation. Using CIU in conjunction with 
HDX-MS provides a comprehensive toolset for analysis of drug substrates to determine optimal 
binding concentrations ideal substrates for a multitude of drug targets. Further work on drug binding 
needs to be done with native MS, as most clinical work employs much lower ratios of drug substrates 
and incubates for shorter time periods before testing occurs, losing critical information about the 
catalytic pathway. 
 
3.6 Methods 
3.6.1 Collision Induced Unfolding Mass Spectrometry of TEM-1 with Inhibitor Substrates 
Trap cone voltage was ramped from 0-100V in 5 V increments on a Waters Synapt G2S with a 
travelling-wave IMS-enabled cell. Scans were recorded in 3-minute increments. TriWave voltage 
remained constant at 400 m/s.  Unbound and substrate-incubated samples were scanned on the 
same day after 10 minutes of incubation. Pulsar software was used to analyze and integrate each 
unfolding plot as a function of arrival time vs. collision energy. The same charge state (+16) was 
selected for each sample and results were recorded in biological replicate. 
 
3.6.2 Native Mass Spectrometry of Inhibitor Binding  
Protein was prepared and buffer exchanged as previously described in print55 and in section 2.5.1. 
Protein concentration was determined by Bradford assay and diluted to a range of 30µM-150µM prior 
to incubation with substrate in either a 10:1 or 1000:1 molar ratio based on ratios previously used in 
pharmaceutical trials that exhibited complete inhibition220,227. Substrates were dissolved in 200mM 
ammonium acetate (to match buffer conditions of the protein). Experiments were repeated in 
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technical and biological triplicate to verify results. Images were prepared using mMass234 and Sigma 
Plot.  
 
3.6.3 Data Analysis of Global and Local HDX  
All HDX work was carried out in biological replicate with a source condition of 2700V capillary voltage 
and 100V sampling cone in positive ion mode. Experiments were performed using the nanoESI source 
on a Synapt G2 Q-Tof instrument with IMS-enabled workflow throughout. Mass spectrometry 
deuterium analysis was performed by Mass Spec Studio235. Peptide fragments were confirmed by 
MS/MS. mMass and MassLynx were used to visualize the native protein spectrum and mass shifts 
with substrate incubation. 
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Chapter 4 
 
Monitoring Catalysis and Associated Conformational 
Effects in Yeast Alcohol Dehydrogenase by Millisecond-
Scale HDX Mass Spectrometry 
 
A version of this chapter has been prepared in manuscript format.  
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4.1 Summary 
Hydrogen/deuterium exchange is one of the few analytical techniques that can capture transient 
intermediates for enzymatic systems. By combining global and local HDX workflows, we aim to 
discover regions essential for catalysis that are traditionally inaccessible by techniques such as 
NMR or X-ray crystallography. Having previously established the presence of a kinetic isotope 
effect in the yeast alcohol dehydrogenase (YADH) oxidation of ethanol by substitution with 1,1-
D2 ethanol 85, we aimed to identify the dynamics of intermediates on the slower timescale 
provided by the deuterated substrate. Using a time-resolved microfluidics device to capture 
deuterium uptake on the millisecond timescale allowed us to observe the rigidifying effect of 
NAD+ binding within the binding pocket and the catalytic zinc to facilitate the required hydride 
transfer between NAD+ and ethanol. Within the same timeframe, we isolated a region (residues 
259-268) that was found to have a significant decrease in dynamics due to the deuterated 
substrate, suggesting a link between the rigidification near the core and a requirement for 
increased flexibility in the outer regions to relieve the steric strain caused by catalysis. 
 
4.2 Introduction 
Decades of research has been geared towards the challenging task of observing protein dynamics 
while they facilitate enzymatic reactions with incredible speed and efficiency. Making structural 
arguments about protein function during a catalytic timescale has proven immensely difficult. It 
is postulated that amide bond fluctuations (on the ps-ns timescale) influence global dynamics236, 
and many kinetic studies have proven the turnover rate of enzymes on the ms-s timescale, 
making techniques such as NMR and conventional HDX unable to provide definitive arguments 
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to the behaviour of enzymes during catalysis. For identifying structural regions of importance, 
CPMG relaxation and X-ray crystallography can help with the identification of binding regions, 
but not necessarily with the transient intermediates or isotopic effects that occur during 
turnover. Alcohol dehydrogenases (ADHs), responsible for the redox reaction between alcohols 
and aldehydes to energy transport molecules (NADH and FADH2)155  are found in a variety of 
forms in nature, most commonly in dimeric form (higher eukaryotes) and tetrameric (prokaryotes 
and lower eukaryotes)165. Although there are a wide variety of ADHs, many published studies 
have examined horse liver ADH (HLADH) due to the early publication of its crystal structure171. 
Horse liver is an ADH sequentially similar to yeast ADH, except for a deletion of 21 residues within 
the catalytic region (residues 1-175, 319-374) and a dimeric form165,167,237. Characterization of 
yeast alcohol dehydrogenase (YADH) provides a greater challenge when attempting to observe 
the dynamic nature of the protein during catalysis: it is twice as large as HLADH, has higher 
substrate specificity for alcohols237 and is 100x more active238.  
 
Yeast produces 3 isozymes of ADH; ADH1 and ADH2 are produced in the cytoplasm (and 
repressed by high glucose levels), while ADH3 is found in the mitochondria and expressed in 
much smaller quantities239–241. It was originally thought that ADH1 and ADH2 were separately 
involved in the oxidation pathway, with ADH1 carrying out the reduction of NAD+ and ADH2 
performing the opposing oxidation of NADH166. This theory has been disproven and now it is 
widely understood that the catalysis occurs through a bi-bi sequential mechanism175,181, with 
both ADH1 and ADH2 capable of carrying out the reversible redox reaction. Herein we 
experiment with the ADH1 isozyme to distinguish the role that a reduction in conformational 
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dynamics (due to the kinetic isotope effect of D2-EtOH) will have in isolating specific regions in 
YADH that are necessary for hydride transfer during catalysis. 
 
4.3 Results  
Catalysis by YADH has multiple components which makes its characterization difficult in isolation: 
zinc atoms are necessary for catalysis and structural support, NAD+/NADH as a coenzyme, and 
alcohol/aldehyde for the hydride transfer to occur. Each monomer of YADH contains 2 zinc 
atoms, with different functions: 1 zinc atom is necessary for catalysis (facilitating the alcohol 
docking)242, while the other zinc atom is responsible for maintaining structural integrity243. The 
distal (structural) zinc is coordinated to 4 cysteine residues (Cys97, Cys100, Cys103 and Cys111, 
figure 4.1)168,242,244,245. The catalytic zinc binds Cys46, His67 and Cys174 to maintain a strained 
conformation within the active site of the open dimer, along with polarizing the carbonyl of the 
incoming alcohol substrate to assist the hydride transfer246–251.  
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Figure 4.1 Schematic of Residues of Interest in Reduction of NAD+ to NADH Although YADH 
operates as a homotetramer, within each dimer there are both open and closed forms. This 
schematic is showing the open conformation of the binding pocket observed in the dimer, with 
NAD+ (blue) bound. Catalytic zinc for the open conformation is in an inverted position, with 
binding to different cysteine residues (Cys43, Cys153)247. A) NAD+ bound with the hydrophobic 
regions (green) highlighted. B)  NAD+ bound with zinc atoms (red) coordinated and cysteine 
residues (purple) highlighted. 
 
NAD+ binds within the βαβ-fold of the interdomain cleft163,252, nearby to the hydrophobic binding 
site pocket (containing Trp54, Trp92, Met270, Tyr294, figure 4.1). The face of the NAD+ ring is 
positioned towards the active site, very close to the Cys46 and Cys174 that coordinate with the 
catalytic zinc in the closed conformation of the homotetramer239. In addition to the 
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hydrophobicity, an accumulation of negative charges  (residues Cys46, Lys174, Glu68, Asp49) 
helps generating a dipole moment to help with the hydride transfer to NAD+253. Another 
important residue for this catalytic mechanism is Val203, well-documented as being important 
for facilitating the hydride transfer between NAD+ and ethanol; the large size and hydrophobicity 
of this residue is opposing NAD+ and aids in the narrowing of the interdomain cleft164 that 
promotes tunneling behaviour173,179,245,254.  
Kinetically, the oxidation of NADH (and correspondingly the reduction of acetaldehyde to 
ethanol) is the favoured reaction in this reversible redox pathway255,256. By introducing the 
substrate after the NAD+ cofactor is bound, we force the reaction to occur in the NADH-favoured 
direction. By using ethanol as the catalytic substrate, we aim to develop a baseline for the highest 
potential difference in dynamics observable by HDX, as ethanol is the most active substrate with 
YADH and most dehydrogenases246,257. 
 
4.3.1 Optimization of the Oligomeric YADH 
Although the catalytically competent form of YADH is the homotetramer43,243, it is difficult to 
observe this macromolecular assembly by mass spectrometry. Even employing ESI-MS as a soft 
ionization technique for generating spectra of the native protein, separation of dimers and 
tetramers is possible in the gaseous phase with minimal energy applied. Without extensive 
optimization of ionization conditions, YADH is observed primarily in monomeric form (figure 4.2, 
top), with some smaller populations of dimer and tetramer.  
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Figure 4.2 Optimization of Oligomeric Forms of Yeast Alcohol Dehydrogenase Top) Raw native 
mass spectra for YADH, with monomeric, dimeric and tetrameric forms labelled. Inset (top right) 
is the native spectra of the same sample with NAD+ incubation, with number of NAD+ molecules 
bound to YADH highlights as blue dots on the crystal structure (PDB ID: 5ENV in dimeric form, 
4W6Z in tetrameric form). Bottom) Same YADH sample with optimization of the ionization 
parameters to obtain only tetrameric form. Inset (top right) is the NAD+ bound complex, with the 
tetrameric NAD+ occupancy being favoured.  
 
It is apparent in figure 4.2 that the complete NAD+ occupancy is not favoured under the initial 
conditions shown in the top of figure 4.2.  Backing pressure was increased on the Synapt G1 to 
reduce the speed at which the high mass homotetramer was travelling through the ToF, slowing 
down the free path enough to allow the detector within the instrument to detect the oligomeric 
form that is observed in the biological environment- the homotetramer, composed of 4 units of 
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identical monomer42,258. After optimization, tetrameric YADH appears in the charge state region 
of 20-27 as reported previously, with 2 zinc ions bound per monomer43,259. We also observe an 
increase in apo-enzyme bound-NAD+ (figure 4.2, bottom inset), showing a favouring of complete 
NAD+ occupancy with the homotetramer. The experiment was optimized to determine the 
minimum timeframe necessary to have complete (or near complete) NAD+ binding. In brief, an 
effective concentration of 400 µM of NAD+ was added to the YADH solution (10 µM starting 
concentration) and incubated for 15 minutes prior to acquiring the mass spectra. These 
instruments conditions were maintained throughout subsequent experiments with HDX, with 
native mass spectra of the homotetramer recorded prior to beginning any HDX experiments.  
4.3.2 Global HDX of YADH Catalysis 
Hydrogen/deuterium exchange experiments studying dynamics of ADHs have been performed in 
the traditional fashion of a s-hrs timescale, but never local and global HDX experiments combined 
for this type of enzyme172. Experiments studying the KIE of ADHs have been of particular interest 
due to the quantum mechanical nature of ADHs; with deuterated substrate and increased 
temperatures, enhanced tunneling to carry out the hydride transfer has been noted, especially 
with yeast ADH164,171,180,260,261. Using an excess of coenzyme (40:1 molar ratio of NAD+ to YADH) 
we were able to demonstrate NAD+ occupancy (described fully in section 4.6.1) prior to the 
deuteration event without the NADH signal overpowering the protein ionization at 666 m/z. 
Given the concentration of NAD+ used and our experimental TRESI workflow a kcat of 380 s-1 was 
established for HDX experiments using YADH85.   We recorded deuterium uptake with several 
time points before and after turnover and hydride transfer is expected to occur.  
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As observed in figure 4.2, there are a couple of different occupancy possibilities for the tetrameric 
form of YADH, (NAD+)2 and (NAD+)4 being the two major forms. Although previous research has 
described the full (NAD+)4 occupancy as being the most common distribution when catalytically 
active85, we wanted to determine if ethanol would be able to be oxidized as efficiently regardless 
of NAD+ occupancy using our millisecond-scale ESI workflow.  
 
Figure 4.3 Global HDX results for (NAD+)2 occupied YADH. Global HDX mass increases were 
captured on the same timescale as local HDX results in triplicate. Apo enzyme (black) has both 
the largest increase in dynamics and most rapid onset, while holoenzyme (blue) displays the 
opposite. In between, D2-EtOH catalysis (red) has a slightly larger amplitude of dynamic increase 
than EtOH catalysis (green) during catalysis, with lower dynamics as the reaction goes to 
completion.  
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With partially occupied tetramer, all 4 experimental runs displayed significantly different uptake 
and dynamics during the catalysis timeframe, with the D2-EtOH sample having the largest 
catalytic amplitude of dynamics. However, the D2-EtOH sample reaches a plateau of approx. 500 
Da after 200 ms, a much smaller increase in deuterium uptake when compared to the non-
deuterated sample at the same time point.  In comparison, the EtOH-catalysis sample had slower 
dynamics during catalysis than the D2-EtOH sample, however it behaved similarly to the apo-
enzyme in the timeframe after the turnover event had occurred. The holo-enzyme form has a 
maximum mass increase of 474±18.4 Da, much lower than the apo-enzyme with 705±49.6 Da.  
From the same experiments, the mass increases corresponding to the deuteration of the (NAD+)4 
tetramer were also recorded and provided somewhat different results.  
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Figure 4.4 Global HDX Results for YADH with (NAD+)4 occupancy during catalysis. Global HDX 
mass increases were captured on the same timescale as local HDX results in triplicate. Apo 
enzyme (black) has both the largest increase in dynamics and most rapid onset, while 
holoenzyme (blue) displays the opposite. In between, D2-EtOH catalysis (red) has a much larger 
amplitude of increase in dynamics than EtOH catalysis (green), while having similar dynamics in 
the lag phase of catalysis. 
 
Once again in figure 4.4, we see a rigidification of the holo-enzyme with NAD+ occupying the 
hydrophobic binding pocket, plateauing with a mass increase of 433±36.8 Da, a similar value 
compared to the (NAD+)2 sample. The catalytic samples behave much more similarly with 
complete (NAD+)4 occupancy, with limited significant results demonstrated between the EtOH 
and D2-EtOH samples in this timeframe. These results are in line with previous research carried 
out by our group178 and lead us to a further exploration of the local HDX dynamics to determine 
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if more localized information on the conformational dynamics would lead to residue-specific 
identification of regions involved in the formation of transient intermediates.  
By comparing the difference in local deuterium uptake relative to the holo-enzyme form, it allows 
us to negate the effect of the rigidification due to the docking of the molecule NAD+ and focus on 
changes in protein dynamics relevant to the addition of deuterated and non-deuterated ethanol 
for catalysis. Experimental conditions were kept identical to the global HDX experiments, with 
the addition of an acidic quenching step and proteolytic digestion chamber (see section 4.6.2).  
 
4.3.3 Local HDX of YADH Catalysis 
Using our microfluidics workflow that enables hydrogen/deuterium exchange on the millisecond 
timescale allows us to monitor protein dynamics as catalysis is occurring85,199,223. As we have 
already determined the kinetic isotope effect of D2-EtOH in YADH catalysis, we now seek to 
demonstrate on a localized level how this influences the dynamic nature of the protein.  
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Figure 4.5 Single Time Point Local HDX Results for EtOH Catalysis Top) Mapped results of the 
local HDX deuterium uptake for 3 time points (87, 135 and 183 ms) during catalysis in one 
monomer, with dynamics > 2σ mapped to the crystal structure (red is increasing dynamics, blue 
is decreasing dynamics). Bottom) Local HDX results prior to NAD+ turnover with peptide-level 
changes in deuterium uptake. Regions of colour indicate statistically significant results (> 2σ). 
The black line outlines the 2σ confidence interval, n=9. 
 
The 3 timepoints examined in figure 4.5 above fall within the timescale of hydride transfer 
occurring. Of note are the regions that are displayed in colour (red is an increase in deuterium 
uptake relative to the holo-enzyme, blue is a decrease in uptake) that have been discovered as 
statistically significant in biological replicate. Regions around the catalytic zinc atom (red sphere, 
centre) have increased dynamics in the first 2 images, with the structural zin (red sphere, bottom) 
having opposing dynamics. Figure 4.5 gives a good example of the difficulties with using 
millisecond-scale HDX for identifying regions of catalysis- often the residues that are isolated as 
being statistically significant relative to the holo-enzyme results (>2σ) are not dynamics seen 
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consistently throughout the catalysis process. For example, there has been much debate over 
the properties of the zinc coordination for catalysis: it is well-established that is necessary for 
catalysis242, but it may either be involved in facilitating deprotonation of ethanol for 
oxidation246,247 (which would cause an increase in dynamics as coordination to cysteine residues 
is disrupted with the incoming ethanol) or in generating a fixed strained conformation necessary 
through coordination to several residues for stability during catalysis (which would cause a 
rigidification and decrease in dynamics)248.  
 
 
Figure 4.6 Single Time Point Local HDX Results for D2-EtOH Catalysis Top) Mapped results of the 
local HDX deuterium uptake for 3 time points (87, 135 and 183 ms) during catalysis in one 
monomer, with dynamics > 2σ mapped to the crystal structure (red is increasing dynamics, blue 
is decreasing dynamics). Bottom) Local HDX results for D2-EtOH catalysis prior to NAD+ turnover 
with peptide-level changes in deuterium uptake. Regions of colour indicate statistically significant 
results (> 2σ). The black line outlines the 2σ confidence interval, n=9. 
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One region (residues 2-12) becomes rigidified by 135 ms in both D2-EtOH and EtOH experiments 
(figures 4.5 and 4.6, middle panel). Once again, figure 4.6 demonstrates that regions involved in 
temporary dynamics (corresponding to transient intermediates) may not carry over to longer 
timepoints of deuteration.  
 
4.4 Discussion  
4.4.1 The Structural Implications of NAD+ Docking 
There are some striking observations to be made when comparing figures 4.3 and 4.4. While the 
holo and apo-enzyme forms exhibit similar dynamic behaviour upon HDX incubation in the 
hydride transfer phase of catalysis, the holo-enzyme (with NAD+ bound) is approximately half as 
dynamic as the apo-YADH, regardless of the number of NAD+ molecules bound. It has been 
previously noted that the binding of NAD+ causes a decrease in YADH dynamics262. This “locking 
in” dynamic with 2 NAD+ molecules bound may suggest that each monomer within the tetramer 
is achieving binding at one site- likely the NAD+ binding area responsible for the interdomain cleft 
narrowing to facilitate ethanol catalysis164. When examining the local HDX dynamics of NAD+-
bound YADH relative to the apo-enzyme, there are only a few residues responsible for the overall 
decrease in dynamics: residues 35-44, 77-87, 137-146 and 211-219. 
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Figure 4.7 Rigidification of YADH with NAD+ Incubation Regions of rigidification relative to apo-
YADH with NAD+ incubation are mapped in blue. Most of the rigidification with NAD+ bound is 
observable in the region around the catalytic zinc (coordinated to Cys43, Cys153). A 180o rotation 
is displayed on the crystal structure (PBD ID: 4W6Z) to properly display the rigidification of the 
unstructured region on the other side of the NAD+ binding pocket. 
 
Another difference of note is the rapid onset dynamics of hydride transfer with (NAD+)2 compared 
to (NAD+)4. It is already well established that complete NAD+ occupancy is necessary for catalysis, 
so observing an increase in dynamics with the deuterated ethanol catalysis with only half 
occupancy is opposing to the current understanding. One possible explanation would be that the 
lack of co-factor in half of the YADH protein (potentially in the closed form) opens the protein up 
to more dynamics in the region where the hydride transfer occurs in the open form, with the 
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inverted zinc conformation that binds Cys43, Cys153 and His66 instead of Cys46, His67 and 
Cys174165,249. This theory is further enforced by the behaviour of the D2-EtOH experiment (red 
line, figure 4.3) as the experiment exceeds the timeframe for hydride transfer. After the first few 
timepoints, when turnover has occurred, we observe a significant drop in the amplitude of 
deuterium uptake for the deuterated vs. non-deuterated catalysis. This could suggest that when 
NAD+ is occupying the binding pockets of the tetramer, the open form is favoured to be occupied 
in each dimer prior to filling the closed form of the tetramer.  
 
4.4.2 Subtleties in Local Dynamics During Catalysis 
In addition to examining global dynamics results that average the dynamic nature of the 
tetramer, we sought to localize results by carrying out bottom-up HDX. A kinetic isotope effect in 
the YADH catalysis of alcohols has been proven by numerous researchers85,162,164,175, but the local 
effect of this decrease in catalysis has yet to lead to identification of residues associated with the 
reduction of dynamics. Deuterium uptake on the amino acid-level (seen in figures 4.5 and 4.6) 
produced fewer significant differences between isotopic forms of ethanol, likely due to an 
averaging of local results over the homo-tetrameric form (as there is no way to separately analyze 
the 4 monomers operating cooperatively, which may have differing catalytic activity).  
One region of interest is residues 234-247, which have a decrease in dynamics with both EtOH 
and D2-EtOH as substrates. This partially unstructured region that encompasses the NAD+ binding 
pocket has been recorded as necessary for efficient NAD+ reduction, and is conserved in all NAD-
dependent enzymes263. Rigidification of this region is in line with our past discussion to the 
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decreased dynamics associated with maintaining NAD+ in the binding pocket when substrate 
enters to ensure catalysis occurs. 
The hydride transfer (time points occurring before 0.3 s) is thought to cause an increase in 
dynamics around the NAD+ molecule, as the NAD+ undergoes considerable strain during hydride 
transfer and potentially changes into a boat configuration in the transition state to facilitate the 
hydrogen transfer from the α-carbon of the alcohol and the C4 of NAD+ (2.7 Ȧ apart)175. However, 
as depicted in figure 4.7, we see a “locking in” of the NAD+ molecule around the binding pocket 
that would infer that both NAD+ and the catalytic zinc have limited activity without the presence 
of the catalytic substrate. 
Since we are unable to distinguish any regions of dynamics unique to D2-EtOH from comparing 
each experiment to each other under the same conditions, we sought an alternate way to 
examine the magnitude of the changes in dynamics. By taking a ratio of the absolute deuterium 
uptakes for both catalytic reactions, we can isolate which regions are exclusive to differences in 
the ethanol structure, instead of the NAD+ binding alone. By taking the fraction 
𝐸𝑡𝑂𝐻
𝐷2−𝐸𝑡𝑂𝐻
 and 
accounting for the error associated with the biological replicate, any regions that exhibit a value 
above 1 would demonstrate a reduction in dynamics associated exclusively with the D2-EtOH 
hydride transfer.   
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Figure 4.8 Isolation of Dynamics Associated with the Deuterated Ethanol During Catalysis Left) 
Crystal structure of dimeric YADH with NAD+ bound (orange). Zinc atoms (red spheres) are shown 
for each monomer. The β-sheets in red correspond to residues 259-268. Right) Ratio of absolute 
deuterium uptake values for YADH-enabled catalysis of EtOH and D2-EtOH.  
 
Although residues 259-268 are not known to be involved in catalysis through interactions with 
the incoming substrates or coordination to zinc atoms, they are spatially close to the NAD+ 
binding pocket. Figure 4.8 highlights the region in both monomers of this dimeric image.  This 
region is mostly composed of non-polar residues (Val259, Gly263, Thr264, Thr265, Val266, 
Leu267, Val268), suggesting limited bonding ability with the adjacent ADH monomer by hydrogen 
bonding as the β-sheet in the crystal structure would suggest (although hydrogen-bonding is seen 
in other ADHs)252. Since these β-sheets are essential for linking the dimer together (and 
subsequently, the homo-tetramer), we postulate that using a substrate that slows down 
dynamics of catalysis allows us to observe the flexibility of quaternary structure farther away 
from the binding region; as the region around the NAD+ molecule rigidifies to enable the hydride 
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transfer to occur, outer regions increase their dynamic nature to relieve conformational strain 
brought on by the incoming substrate into the binding region.   
 
4.5 Conclusions 
Being able to measure the conformational dynamics of yeast alcohol dehydrogenase catalysis 
and correlate these results with structural studies is a challenging feat. The quaternary structure 
is sensitive to instrument conditions and easily disassembled, while catalysis requires the 
addition of 2 substrates to initiate the bi-bi mechanistic sequence. By introducing ethanol into 
our HDX microfluidics device after the incubation of NAD+ we were able to force the oxidation of 
ethanol-favoured reaction and map the dynamics of catalysis with deuterium labelling. Results 
herein provide evidence to the necessity of rigidification around the catalytic zinc and NAD+ 
molecule before and during catalysis, along with an order of NAD+ occupation in the quaternary 
structure. Although there were limited significant results on a localized level using HDX to 
differentiate catalysis with EtOH and D2-EtOH, nonetheless by slowing down the dynamics of 
catalysis we were able to gain insights into the conformational changes that exist within each 
monomeric unit. We postulate that while the NAD+ associated residues require a more structured 
protein for effective positioning to facilitate hydride transfer, the outer regions will have an 
increase in dynamics to compensate for the steric strain imposed by the substrate. Further work 
could be done with larger alcohol substrates that will not be catalyzed as quickly, such as a benzyl-
alcohol.  
 
 
103 
 
4.6 Methods 
Yeast alcohol dehydrogenase (A3263) and β-nicotinamide adenine dinucleotide hydrate (N7004) 
and HPLC-grade ethanol (99%) were purchased from Sigma Aldrich. 1,1 D2-EtOH (98%, 1859-09-
2) ampules were purchased from Cambridge Isotope Laboratories. 
4.6.1  Oligomeric Optimization Through Back Pressure Manipulation 
Source conditions were the following: 3.0 kV at the capillary, 200 V at the sample cone, 1.0 V at 
the extraction cone and a desolvation temperature of 125o C.  Several rounds of optimization 
were carried out and back pressure was increased on the Synapt G1 ToF to reach 5.2 mBar with 
a trap pressure of 7.75x10-3 bar prior to recording spectra. Trap and transfer collisional voltages 
were 7V and 5V, respectively. Native mass spectra was recorded with an enhanced duty cycle at 
4000 m/z to increase resolution at this m/z to determine NAD+ binding. 
4.6.2 Global HDX of YADH 
Experiment were primarily carried out on the Synapt G1 ToF mass spectrometer. For sample 
preparation, YADH (20 µM in 100 mM ammonium acetate, pH 7.0) was desalted using a 7K 
MWCO Zeba column. To record the apo-enzyme spectra, the stock solution was further diluted 
in 100mM ammonium acetate to 2 µM. For the holo-enzyme sample, YADH was incubated with 
NAD+ in a molar ratio of 40:1 NAD+ to YADH for 15 minutes, with NAD+ having an 80 µM effective 
concentration upon dilution. For experiments with EtOH/D2-EtOH, a stock solution of 250 mM 
EtOH was prepared daily. EtOH was mixed into the deuterium channel in order to react with 
YADH + NAD+ as HDX was being recorded, having an effective concentration of 200mM upon 
mixing. Protein syringe was operating at a flow rate of 4 µL/min, while the deuterium syringe 
(with and without ethanol added) was flowing at 16 µL/min, proving an 80% deuteration rate.  
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Mass shifts were recorded and displayed as spectra in MassLynx. Kinetic results were displayed 
using SigmaPlot.  
4.6.3 Local HDX Workflow 
Experiments were primarily carried out on the Synapt G2 ToF mass spectrometer. Substrate 
concentrations and flow rates remained the same as the global HDX experiments, with the 
addition of a quenching and digestion step as described in Chapter 2. The deuterated sample was 
quenched by 5% acetic acid (pH 2.4) and a TRESI-workflow,  with source conditions described 
elsewhere55. Capillaries were cleaned with solvent, acetonitrile and distilled water washes 
between every change in substrate to ensure no carry over of products or aggregates. The IMS 
cell was enabled for MS/MS identification of peptides. MS/MS results were recorded by Peter 
Liuni on an Orbitrap instrument from a digested protein sample of 100 fM/µL. Deuterium uptake 
was quantified using MassSpec Studio software.  
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Chapter 5 
Conclusions and Future Work 
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5.1 Summary 
Using a millisecond-scale analytical technique is of tremendous utility for studying protein 
dynamics. The work herein uses Hydrogen/Deuterium Exchange as a bioanalytical technique to 
further our advancement of drug design and give evidence to the conformational dynamics 
associated with enzymatic systems. In Chapter 1 we introduce HDX-MS as a tool for studying 
protein dynamics in a biologically suitable environment. We describe the pairing of this analytical 
technique on-line with microfluidic devices, and the impact of new device implementation on 
drug discovery efforts. This is followed by introductions into the enzymatic systems involved in 
antibiotic resistance and energy production, providing a link between their function and 
observable dynamics.  
In Chapter 2, knowledge of the mechanistic processes surrounding substrate hydrolysis by TEM-
1 was used to inform a correlation between binding modes and specific conformational dynamics 
with steady-state kinetics. We sequester dynamics associated with binding, productive acylation 
and inhibition to determine how different drug families interact with TEM-1 β-lactamase in an 
attempt to design new drug substances with more complex modes of inhibition. Of interest is the 
discovery of a requirement for rigidification of H11 for inhibition of TEM-1, the only region 
discovered so far as having allosteric influence on the binding site. We also examined direct 
evidence of a difference in turnover rate observed using our kinetic-HDX workflow to correlate 
an increase in cephalosporin activity associated with increased dynamics in within the protein 
core. 
There are several complementary techniques for analyzing proteins in addition to local HDX 
experiments, such as studying the binding affinity of substrates and monitoring conformational 
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change associated with binding by IMS-MS. In Chapter 3, we further expand on the study into 
TEM-1 by examining quaternary structural interactions by CIU-MS, a form of IMS-MS. The impact 
of different inhibitors and our shortcomings in pharmaceutical studies as a community are 
discussed. In particular, the molar ratio of inhibitor: enzyme must be consistently monitored 
across pharmaceutical trials to have confidence that similar mechanistic pathways are being 
employed in the protein of interest. Native mass spectrometry is a straightforward technique 
that provides direct evidence of different binding products over time when comparing difference 
substrates at varying concentrations. By using CIU-MS in conjunction with local and global HDX 
we correlated specific inhibitory byproducts to the residues at which they inhibit, providing a 
definitive mechanistic byproduct formation pathway. By using a time resolved HDX method, we 
were also able to isolate the regions essential for complete inactivation, not just the global 
rigidification effect observed.  These byproducts can then be ranked in order of potency, relating 
the CIU results to the native binding study. 
Many complex enzymatic systems require a large quaternary structure and coenzymes in order 
to perform catalytically in vivo. In Chapter 4, we utilized time resolved local HDX in conjunction 
with global HDX to monitor the conformational dynamics associated with catalysis in a large 
homotetramer, yeast alcohol dehydrogenase. The dynamics associated with coenzyme binding 
were measured prior to making conclusive statements regarding the dynamics associated with 
hydride transfer. Global dynamics with complete and half occupancy of NAD+ within the 
homotetramer provided differing results for the catalytic substrate, suggesting a preferred 
binding of NAD+ within the open form prior to occupying the NAD+ binding area of the closed 
form of the tetramer to assist the catalytic zinc. In addition, we examined the local impact of 
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reduced dynamics due to deuteration of the ethanol substrate on the hydride transfer between 
ethanol and NAD+.  
5.2 Future Work 
The advent of microfluidic devices for use in bioanalytical chemistry has led to great advances in 
our knowledge of protein: ligand complexes and the conformational dynamics of a multitude of 
proteins under various reaction conditions. As discussed throughout this dissertation, 
microfluidic workflows enable measurements of protein dynamics that are traditionally 
inaccessible by other analytical techniques. Microfluidic devices and workflows enable increases 
in sensitivity and time before analysis prior to entering the analytical instrument87, having the 
potential of being very impactful in medical research. For medical applications, microfluidic 
devices aid in the separation of analyte of interest from a complex biological solution264, give 
rapid detection against infections265, aid in the study of cellular death in chemotherapy266,  and 
in diabetes treatment267  and gene sequencing268. Herein we describe an extension of this 
microfluidics science to complex enzymatic systems usually confirmed to tropical medicine.  
 
5.2.1 Combatting Drug Resistance in Tropical Medicine 
Tropical medicine is a crucial subset of drug development that requires additional academic 
research funding, primarily due to the lack of interest from pharmaceutical companies. In a world 
of almost 7 billion people, half lack basic sanitation and over 1 billion lack basic healthcare 
services and clean drinking water269. It is particularly difficult to measure the impact of a drug 
product on an individual patient in tropical illnesses, as most parasitic organisms operate through 
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such complex enzymatic pathways that immune responses (and subsequent affinity to 
medicines) vary widely, especially in patients already immunocompromised270–272.  
 
5.2.2 Leishmania Overview 
More than 50% of deaths in the worlds poorest countries are the result of infectious diseases269. 
Leishmania is a protozoan parasite transmitted to humans and other mammalian hosts through 
the bite of phlebotomine sandflies, causing leishmaniasis (skin ulcers)271,273. Commonly referred 
to as a “poverty-related” disease, Leishmania affects over 150 million people worldwide, with 
350 million people at risk of developing the disease and anywhere from 26,000-65,000 deaths 
annually274. In humans, there are 21 pathogenic species of leishmania that inhibit cytokine-
inducible macrophage functions necessary for immune response to an invasive species along with 
an inhibition of nitric oxide prodution275. Several of the on the market drug treatments are 
exorbitantly expensive and highly toxic, relying on heavy metal dosage and the production of 
several byproducts that may cause additional membrane damage272,276,277. Due to the high 
toxicity and complex reactions possible on an individual basis, further research should be carried 
out into the initial assessment of drug product to pre-select an optimal drug product for the 
individual patient based on a rapid screening of immune response to a variety of potential 
medications.  
 
5.2.3 Microfluidic Design Proposal for Changing Environmental Conditions 
Not only are there a multitude of potential immune responses to medications, there are also 
changes to the parasite cellular shape and function as it travels to different hosts and is exposed 
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to difference acidities and temperatures278. In the sandfly, the parasite is exposed to a basic 
environment, while in a macrophage phagolysozyme the parasite has acidic surroundings.  
From a pharmaceutical development platform, we propose the addition of an acidic incubation 
chamber subsequent to an initial chamber containing mammalian-cell conditions, to monitor 
conformational changes to proteins of interest in both host and pathogenic environments by a 
variety of techniques, such as HDX-MS or flow cytometry coupled to MS. Unfortunately, rapidly 
changing acidity would not be favourable to a polymer chip, so silicon and glass chips with a 
higher labour cost would be advised for pharmaceutical development. 
 
5.2.4 Microfluidic Design Proposal for Simultaneous Host Environment Diagnostics 
The primary challenge associated with developing microfluidics for developing countries is the 
point of care (POC) abilities and durability. A useful diagnostic tool must be easy to use, low-cost, 
stable to transport, function with a wide temperature range and be battery operated. These 
characteristics eliminate many current laboratory methods from becoming popular in a local 
community health centre.  
Using our current PMMA chip design would allow for reproducible designs and generate sturdy 
devices that can be produced in large quantities. Original microfluidic devices were prepared 
using silicon, but the use of polymers has widely surpassed this technique due to the easier 
production and lower cost88,279,280. In addition to this durable polymeric structure, adding a new 
ablation pattern that mimics the extracellular matrix would allow for a more detailed 
examination of the environment surrounding the protein/cell of interest. For example, it is 
possible to simulate the microenvironments of multiple types of body tissue (bone, liver, kidneys) 
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to study the toxicity of drug products as they travel through the system to determine potential 
side effects281,282. Once optimized, it could be possible to mass produce the unique microfluidic 
surfaces for differing host environments and solution conditions.  
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Appendix A 
Supplemental Figures for Chapter 2 
 
Supplemental Figure A1 Equilibrated Local HDX Coverage for TEM-1 with Ampicillin. 
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Supplemental Figure A2 Equilibrated Local HDX Coverage for TEM-1 with Cephalexin. 
 
Supplemental Figure A3 Equilibrated Local HDX Coverage for TEM-1 with Clavulanate. 
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Supplemental Figure A4 Kinetic Local HDX Coverage for TEM-1 with Ampicillin after 0.34s of 
deuteration. 
 
Supplemental Figure A5 Kinetic Local HDX Coverage for TEM-1 with Ampicillin after 0.63s of 
deuteration. 
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Supplemental Figure A6 Kinetic Local HDX Coverage for TEM-1 with Ampicillin after 0.88s of 
deuteration. 
 
Supplemental Figure A7 Kinetic Local HDX Coverage for TEM-1 with Ampicillin after 1.54s of 
deuteration. 
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Supplemental Figure A8 Kinetic Local HDX Coverage for TEM-1 with Cephalexin after 0.34s of 
deuteration. 
 
Supplemental Figure A9 Kinetic Local HDX Coverage for TEM-1 with Cephalexin after 0.63s of 
deuteration. 
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Supplemental Figure A10 Kinetic Local HDX Coverage for TEM-1 with Cephalexin after 0.88s of 
deuteration. 
 
Supplemental Figure A11 Kinetic Local HDX Coverage for TEM-1 with Cephalexin after 1.54s of 
deuteration. 
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Appendix B 
Supplemental Figures for Chapter 3 
 
 
 
Supplemental Figure B1 Native mass spectra of TEM-1 incubated with each drug substrate at a 
ratio of 1000:1 inhibitor to TEM-1 on a shorter timescale. Protein spectra at 5 time points (1 min, 
3 mins, 5 mins, 7 mins, 9 mins) are overlaid to demonstrate the small shifts in spectra noted over 
the time course.  
 
146 
 
 
Supplemental Figure B2 Native mass spectra of TEM-1 incubated with each drug substrate at a 
ratio of 10:1 inhibitor to TEM-1 on a shorter timescale. Protein spectra at 5 time points (1 min, 
3 mins, 5 mins, 7 mins, 9 mins) are overlaid to demonstrate the small shifts in spectra noted 
over the time course. 
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Supplemental Figure B3 Equilibrated Local HDX results for Tazobactam incubation (1000:1 
ratio) at the first (0.38s) and last (2.62s) time points recorded using the TRESI setup with 10 
minutes incubation prior to deuteration. Peptide fragments in colour (grey, insignificant; red, 
increasing; blue, decreasing) signify differences in deuterium uptake between the holo and apo 
enzyme forms (>2σ, dotted black line).Pymol image (PBD ID: 1BTL) displays the significant 
changes in dynamics. Regions with no significant change are displayed in gold, decreasing in 
blue, increasing in red and unrecorded regions are in grey.  
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Supplemental Figure B4 Equilibrated Local HDX results for Sulbactam incubation (1000:1 ratio) 
at the first (0.38s) and last (2.62s) time points recorded using the TRESI setup. Peptide 
fragments in colour (grey, insignificant; red, increasing; blue, decreasing) signify differences in 
deuterium uptake between the holo and apo enzyme forms (>2σ, dotted black line).Pymol 
image (PBD ID: 1BTL) displays the significant changes in dynamics. Regions with no significant 
change are displayed in gold, decreasing in blue, increasing in red and unrecorded regions are 
in grey.  
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Supplemental Figure B5 Equilibrated Local HDX results for Clavulanate incubation (1000:1 ratio) 
at the first (0.38s) and last (2.62s) time points recorded using the TRESI setup. Peptide 
fragments in colour (grey, insignificant; red, increasing; blue, decreasing) signify differences in 
deuterium uptake between the holo and apo enzyme forms (>2σ, dotted black line).Pymol 
image (PBD ID: 1BTL) displays the significant changes in dynamics. Regions with no significant 
change are displayed in gold, decreasing in blue, increasing in red and unrecorded regions are 
in grey.  
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Supplemental Figure B6 CIU Heat Maps of Binding Affinity for TEM-1 and Inhibitors. Top) CIU 
spectra of inhibitor-bound TEM-1 for the 1000:1 experiment at collisional voltages from 0-100 
V, taken in 5V increments. Inset into each CIU plot is a magnification of the unfolding 
conformations occurring in the lower 0-50 V range. Changes in folding states are outlined with 
the dotted white line. All spectra were recorded for the +16-charge state. Bottom) CIU spectra 
of inhibitor-bound TEM-1 for the 10:1 experiment, with identical voltage increments and charge 
state selection as the 1000:1 presentation. 
 
 
 
